Section 3 of 6
Product information and disease description
394 evidence topics · 160 sources
Product description
Phase of product development
Regulatory status: Under review; NDA submitted April 2026, PDUFA target action date April 2027
Launch
No evidence found.
NDA submission, April 2026
FDA acceptance of the NDA and PDUFA target action date, July 2026
NDA review under conventional FDA procedures and timeline
EMA marketing authorization application submitted and validated, October 2026
FDA orphan drug designation, November 2023
| Field | Quoted record |
|---|---|
| Generic name | “varegacestat” |
| Date designated | “11/02/2023” |
| Orphan designation | “Treatment of desmoid tumors” |
| Orphan designation status | “Designated” |
| FDA orphan approval status | “Not FDA Approved for Orphan Indication” |
| Sponsor | “Immunome, Inc.” |
EMA orphan designation: company statement of July 2025 for desmoid tumors
EMA orphan designation: EMA register entry of 22 August 2025 for soft tissue sarcoma
| Field | Quoted record |
|---|---|
| Active substance | “varegacestat” |
| Intended use | “Treatment of soft tissue sarcoma” |
| Orphan designation status | “Positive” |
| EU designation number | “EU/3/25/3127” |
| Date of designation | “22/08/2025” |
| Sponsor | “Somerville Development Partners B.V.” |
Development history: Bristol-Myers Squibb phase 1 trial of BMS-986115
Development history: Ayala Pharmaceuticals license from Bristol-Myers Squibb and design of RINGSIDE
Development history: acquisition by Immunome from Ayala Pharmaceuticals, March 2024
Development history: Amendment No. 4 to the BMS license, October 2026
No product approved for commercial sale
MAA submission planned by the end of 2026, August 2026, superseded in October 2026
MAA submission planned by the end of 2026, May 2026, superseded in October 2026
NDA submission planned for the second quarter of 2026, March 2026, superseded in April 2026
NDA submission planned for the second quarter of 2026, December 2025, superseded in April 2026
Launch preparation anchored to priority review, December 2025, superseded in August 2026
Topline data expected before the end of 2025, November 2025, superseded in December 2025
Topline data expected in the second half of 2025, January 2025, superseded in December 2025
Product information
Generic, brand name and therapeutic class of product
Manufacturer: Immunome
Recommended international nonproprietary name
Originator code BMS-986115 and synonyms
“AL102” (opens the source at this quote in a new tab)
“BMS-986115” (opens the source at this quote in a new tab)
“GS/pan-Notch Inhibitor AL102” (opens the source at this quote in a new tab)
“BMS-986115 is a potent and selective inhibitor of gamma-secretase mediated Notch signalling and inhibits all 4 mammalian Notch receptors (Notch1 to 4) with low nanomolar median inhibitory concentrations (IC50s).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Brand name
No evidence found.
Dosage forms and strengths
Dose administered in the RINGSIDE phase 3 trial
Capsule formulations in clinical pharmacology studies
Capsule strengths of BMS-986115 in the Bristol-Myers Squibb phase 1 trial
Commercial dosage form and unit strengths
No evidence found.
Average sales price and wholesale acquisition cost
Not applicable.
American hospital formulary service (AHFS), or other drug classification
WHO functional classification
National Cancer Institute Thesaurus classification
AHFS classification
No evidence found.
Indication
Proposed indication in the MAA
Population of the RINGSIDE phase 3 trial: adults with progressing desmoid tumors
Registry eligibility for RINGSIDE Part B: age 12 years and older
Pharmacology
Mechanism of action
Gamma secretase inhibition of Notch signaling
Inhibition of all four Notch receptors
“BMS-986115 is a potent and selective inhibitor of gamma-secretase mediated Notch signalling and inhibits all 4 mammalian Notch receptors (Notch1 to 4) with low nanomolar median inhibitory concentrations (IC50s).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“AL101 (formerly BMS-906024) and AL102 (formerly BMS-986115) are structurally similar GSIs that are parenterally and orally administered, respectively, that inhibit activation of all four human Notch receptors” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Wnt/β-catenin and Notch pathway cross-talk in desmoid tumors
“Both sporadic DT and familial adenomatous polyposis (FAP)-associated DT are linked to constitutive activation of the Wnt signaling pathway with mutations in the β-catenin oncogene CTNNB1 or the tumor suppressor gene APC, respectively. Cross-talk between the Notch and Wnt pathways, as well as activation of the Notch pathway resulting from dysregulation of the Wnt pathway, suggest a possible therapeutic target for DT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Due to the role γ-secretase plays in Notch signaling through cleavage of the Notch intracellular domain (with subsequent translocation to the nucleus to activate gene transcription), γ-secretase inhibitors (GSIs) have emerged as a potential treatment for DT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Along with overexpression of β-catenin, desmoid tumors highly express Notch1, with cross-talk between these pathways putatively contributing to proliferation of desmoid tumors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nonclinical studies have shown that γ-secretase inhibition prevents release of the Notch intracellular domain, which blocks Notch pathway signaling and cell growth.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Notch target gene expression in desmoid tumor tissue
“In DT, evidence for dysregulation of Notch signaling was observed in in vitro studies showing that DT tissues expressed higher levels of Notch1 and its downstream target HES1” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Subsequent studies analyzed the expression of Notch pathway components in DT tissues and cell strains, and confirmed increased expression of HES1 in DT versus dermal scar tissue” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mechanistic rationale for gamma secretase inhibitor therapy
Pharmacodynamics
Notch target gene inhibition in peripheral blood
“Target inhibition of Notch pathway related genes was observed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Expression of Notch pathway-related genes in peripheral blood was measured as surrogate PD biomarkers for BMS-986115.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After 2 weeks of dosing at the highest tolerated doses of 1.2 mg QD and 1.5 mg QD, geometric mean relative expression of Hes1 was continuously inhibited by >50% below baseline, with peak inhibition of >80% (Fig. 2). Similarly, geometric mean relative expression of Deltex1 was continuously inhibited by greater than 45% for the entire dosing interval, with peak inhibition of >60% (Fig. 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At the highest tolerated dose level of 4 mg BIW, geometric mean relative expression of Hes1 was inhibited by >75% for at least 48 h of the weekly dosing cycle and Deltex1 was inhibited by greater than 50%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Exposure-response for safety in a pooled phase 1 to phase 3 population
| Adverse event of interest | Incidence, n (%) |
|---|---|
| Treatment-emergent serious adverse events | “49 (31.2)” |
| Grade 2+ hypophosphatemia | “47 (29.9)” |
| Grade 2+ fatigue | “43 (27.4)” |
| Grade 2+ nausea/vomiting | “31 (19.7)” |
| Grade 2+ diarrhea | “59 (37.6)” |
| Ovarian toxicity | “32 (50.0)” |
| Grade 2+ rash | “58 (36.9)” |
| Grade 2+ ALT elevation | “9 (5.7)” |
| Note | “Safety analysis population count was (N = 157) for all endpoints except ovarian toxicity (N = 64).” |
Exposure-response modeling of tumor volume and dose selection
Nonclinical pharmacology and toxicology
“Nonclinical experiments showed that BMS-986115 was effective as a single agent in the treatment of human T-ALL xenograft models, and demonstrated anti-tumour activity against 5 out of 7 solid tumour xenografts evaluated, including 3 breast, 1 NSCLC, and 1 pancreatic carcinoma. In animal studies, the main pharmacological toxicities included dose-dependent gastrointestinal (GI) toxicity, lymphoid depletion, and interruption of ovarian follicle maturation. Notch inhibitor mediated GI toxicity, which is characterized by goblet cell metaplasia throughout the intestines, is the result of on-target drug-induced differentiation of small intestinal and colonic progenitors to the secretory (goblet) cell fate.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Subjects were required to have an adequate lipid profile as increases in triglycerides were seen in the multiple dose rat study with BMS-986115.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacokinetics
Absorption, dose proportionality, and half-life with once-daily dosing
“BMS-986115 was rapidly absorbed following single/multiple-dose administration over the 0.3-mg to 8-mg dose range, and the median Tmax was within a range of 1 h to 3 h. There was a dose-related increase for both Cmax and AUCtau after BMS-986115 administration following single/multiple-dose administration over the 0.3-mg to 8-mg dose range. Following multiple once daily dose administration of BMS-986115, the median half-life ranged from 17.24 h to 28.01 h.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Accumulation with repeated dosing
“BMS-986115 accumulated in plasma following once daily administration in Arms A and B. The median accumulation ratios (AUCtau ratio of Day 15/Day 1 values) of BMS-986115 after once daily dosing were 2.64, 3.9, 3.66, 2.33, and 2.19 for 0.3-, 0.6-, 1.2-, 1.5-, and 2-mg doses, respectively. Accumulation ratios (AUCtau ratio of Day 16/Day 1) of BMS-986115 after two consecutive days dosing in a week (Arm B) were 2.47, 3.01, and 2.77 for 2-, 4- and 8-mg doses, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Active metabolite BMT-100948
“Plasma concentration-time data for BMS-986115 and an equally active metabolite BMT-100948 were reported for subjects who received at least one dose of study medication.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Plasma concentrations of BMT-100948 were low relative to plasma concentrations of the parent drug (BMS-986115). Median Cmax% ratios for BMT-100948 to that of BMS-986115 after a single dose on Day 1 ranged from 5 to 13%, and after multiple doses on Day 15 ranged from 12 to 16%, respectively. Similarly, median AUCtau ratio for BMT-100948 to that of BMS-986115 after a single dose on Day 1 ranged from 14% - 22%, and after multiple doses on Day 15 ranged from 17% - 27%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Projected half-life and rationale for transient target engagement
“As prolonged inhibition of the Notch pathway is associated with increased GI toxicity, an oral Notch inhibitor with a short half-life that allows transient rather than continuous target engagement is desirable. BMS-986115 has a projected human half-life of approximately 15 h” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Half-life relative to nirogacestat as stated by the company
“Varegacestat is a Gamma Secretase Inhibitor with a” (opens the source at this quote in a new tab)
“Differentiated Pharmacokinetic Profile” (opens the source at this quote in a new tab)
“78% Longer Half-Life than” (opens the source at this quote in a new tab)
“Nirogacestat” (opens the source at this quote in a new tab)
“Sustained Exposure Above” (opens the source at this quote in a new tab)
“1.2 mg Once Daily” (opens the source at this quote in a new tab)
“(3) Immunome data on file” (opens the source at this quote in a new tab)
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
Not applicable.
Special populations
Hepatic impairment: single-dose pharmacokinetic study design
Hepatic and renal function thresholds for trial eligibility
Age: eligibility and enrolled age ranges
| Population | Age (years), median (min-max) |
|---|---|
| Efficacy population, varegacestat (RINGSIDE Parts A and B), N = 121 | “40 (18-72)” |
| Efficacy population, placebo (RINGSIDE Part B), N = 77 | “39 (20-69)” |
| Safety population, varegacestat (CA002-001 and RINGSIDE), N = 157 | “45 (18-84)” |
Age subgroups: progression-free survival
Drug/Drug, drug/disease interactions
Effects of other drugs on Varegacestat
Itraconazole interaction study in healthy participants
CYP3A4 and P-glycoprotein inhibitors and inducers as prohibited concomitant medications
“The prohibited concomitant medications included herbal supplements, medications causing Torsades de Pointes, strong inhibitors or inducers of CYP3A4 or P-gp, and sensitive substrates of CYP3A4 with a narrow therapeutic window.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Effects of Varegacestat on other drugs
Sensitive CYP3A4 substrates as prohibited concomitant medications
Itraconazole trough concentrations measured with varegacestat
Dosing and administration
Dosage
Randomized dose and open-label extension dose
Dose selection for the RINGSIDE phase III trial
Dose reduction levels and time to first dose modification
“Median Time to First Dose Reduction” (opens the source at this quote in a new tab)
“to 0.9 mg (n=60): 3.7 (IQR 1.8, 8.3) months” (opens the source at this quote in a new tab)
“to 0.6 mg (n=36): 7.3 (IQR 3.0, 12.5) months” (opens the source at this quote in a new tab)
“Median Time to First Dose Interruption” (opens the source at this quote in a new tab)
“Varegacestat (n=63): 2.5 (IQR 1.0, 5.7) months” (opens the source at this quote in a new tab)
“Dose Reduction” (opens the source at this quote in a new tab)
“Varegacestat 80% | Placebo 9%” (opens the source at this quote in a new tab)
“Dose Interruption” (opens the source at this quote in a new tab)
“Varegacestat 65% | Placebo 14%” (opens the source at this quote in a new tab)
Dose levels and dose modification rules for BMS-986115
“BMS-986115 was administered orally once daily (QD) at doses of 0.3, 0.6, 1.2, 1.5, and 2 mg (Arm A) or twice weekly (BIW) on consecutive days at doses of 2, 4, 8 mg (Arm B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Dose interruption (up to 28 days) and/or dose modification (up to 2 dose reductions) were permitted in the event of study drug toxicity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Administration
Fasting administration in clinical pharmacology studies
Access and distribution
Planned U.S. commercialization through an internal commercial organization
Launch focus on sarcoma centers of excellence
Distribution, supply chain, and commercial supply
Market access and patient support planning
Treatment duration expected in practice
Specialty pharmacy or specialty distributor arrangements
No evidence found.
Co-prescribed/Concomitant therapies
Prohibited concomitant medications and excluded co-medications
“The prohibited concomitant medications included herbal supplements” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“conditions requiring chronic systemic glucocorticoid use, therapeutic anticoagulation, and concomitant second malignancies” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Electrolyte supplementation and medical management of diarrhea
“excluding asymptomatic electrolyte abnormalities that were manageable with appropriate supplements, alopecia and fatigue lasting ≤5 days” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“except hyperlipidemia in subjects not receiving maximum medical management or electrolyte abnormalities that may be managed with supplements” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although Gr 3/4 diarrhoea related to the study treatment was observed in 2 of 7 patients (29%) treated at this dose level, these events resolved to Gr 1 within 24 h with appropriate medical management.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prior and concurrent desmoid tumor therapies excluded from trial eligibility
Analgesic use and anti-infective therapy in trial eligibility
Effect of Varegacestat on quality measures
No evidence found.
Product comparison
Dosing, dosing frequency, and form: varegacestat in RINGSIDE Part B
Dosage form: varegacestat capsule formulations
Dosing, dosing frequency, and form: nirogacestat
Dosing, dosing frequency, and form: sorafenib in the phase 3 desmoid tumor trial
“In this double-blind, phase 3 trial, we randomly assigned 87 patients with progressive, symptomatic, or recurrent desmoid tumors to receive either sorafenib (400-mg tablet once daily) or matching placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Dose interruptions (of up to 28 days) and one dose reduction (to 200 mg once daily) were permitted and described in the trial protocol.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Half-life: BMS-986115 (varegacestat) in the phase 1 trial
Half-life: company claim for varegacestat relative to nirogacestat
Half-life: nirogacestat
Phase 3 efficacy: varegacestat in RINGSIDE Part B
Phase 3 efficacy: nirogacestat in DeFi
| DeFi outcome | OGSIVEO (N = 70) | Placebo (N = 72) |
|---|---|---|
| Patients with a progression-free survival event, n (%) | “12 (17)” | “37 (51)” |
| Median progression-free survival, months (95% CI) | “NR (NR, NR)” | “15.1 (8.4, NR)” |
| Objective response rate, n (%) | “29 (41)” | “6 (8)” |
| Objective response rate, 95% CI | “(29.8, 53.8)” | “(3.1, 17.3)” |
| Complete response, n (%) | “5 (7)” | “0” |
| Partial response, n (%) | “24 (34)” | “6 (8)” |
Phase 3 efficacy: sorafenib
“With a median follow-up of 27.2 months, the 2-year progression-free survival rate was 81% (95% confidence interval [CI], 69 to 96) in the sorafenib group and 36% (95% CI, 22 to 57) in the placebo group (hazard ratio for progression or death, 0.13; 95% CI, 0.05 to 0.31; P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Before crossover, the objective response rate was 33% (95% CI, 20 to 48) in the sorafenib group and 20% (95% CI, 8 to 38) in the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary end point was investigator-assessed progression-free survival; rates of objective response and adverse events were also evaluated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Phase 3 safety: varegacestat in RINGSIDE Part B
Phase 3 safety: nirogacestat in DeFi
“Frequent adverse events with nirogacestat included diarrhea (in 84% of the patients), nausea (in 54%), fatigue (in 51%), hypophosphatemia (in 42%), and maculopapular rash (in 32%); 95% of adverse events were of grade 1 or 2. Among women of childbearing potential receiving nirogacestat, 27 of 36 (75%) had adverse events consistent with ovarian dysfunction, which resolved in 20 women (74%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Phase 3 safety: sorafenib
“Among patients who received sorafenib, the most frequently reported adverse events were grade 1 or 2 events of rash (73%), fatigue (67%), hypertension (55%), and diarrhea (51%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“dose reductions due to toxic effects occurred in 31% (15 of 49) and 11% (4 of 35), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events led to a significantly higher rate of discontinuation of the trial regimen in the sorafenib group than in the placebo group (20% vs. no patients).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Grade 3 adverse events that were attributed to the trial regimen by the investigators occurred in 29% of patients in the sorafenib group and 14% of patients in the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Company cross-trial comparison of phase 3 objective response rates, with its disclaimer
| Phase 3 trial | Year shown | Regimen | Trial and size | Objective response rate, active | Objective response rate, placebo |
|---|---|---|---|---|---|
| Sorafenib | “2018” | “400mg Once Daily Oral” | “NCT02066181; N=87” | “ORR: 33%” | “ORR: 20%” |
| Nirogacestat | “2023” | “150 mg Twice-Daily Oral” | “DeFi; n=142” | “ORR: 41%” | “ORR: 8%” |
| Varegacestat | “2025” | “1.2mg Once-Daily Oral” | “RINGSIDE; N=156” | “ORR: 56%” | “ORR: 9%” |
Company and investigator comparative statements
Wholesale acquisition cost of nirogacestat, January 2026
| Product | NDC | Dosage form and strength | Wholesale acquisition cost |
|---|---|---|---|
| OGSIVEO 100 mg | “82448-0100-14” | “Oral Tablet 100 MG” | “$7,746.58” |
| OGSIVEO 150 mg | “82448-0150-14” | “Oral Tablet 150 MG” | “$7,746.58” |
Wholesale acquisition cost of nirogacestat at introduction, December 2023, superseded in January 2026
Other products in development for desmoid tumors: zolucatetide
Place of product in therapy
Disease description
Definition and etiology
Definition: monoclonal fibroblastic proliferation with a variable clinical course
WHO 2020 classification: intermediate, locally aggressive category
Locally aggressive tumor without metastatic potential
“Although lacking metastatic potential, DT is often locally aggressive and invasive, causing significant morbidity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sporadic and familial adenomatous polyposis-associated desmoid tumors
“Both sporadic DT and familial adenomatous polyposis (FAP)-associated DT are linked to constitutive activation of the Wnt signaling pathway with mutations in the β-catenin oncogene CTNNB1 or the tumor suppressor gene APC , respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Proportion with familial adenomatous polyposis in a Dutch nationwide pathology registry, 1999 to 2009
“Histopathology data of all Dutch patients with desmoid-type fibromatoses diagnosed between 1999 and 2009 were retrieved from PALGA, the nation-wide network and registry of histopathology in the Netherlands.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total number of 519 patients older than 10 years with a confirmed diagnosis of desmoid-type fibromatoses were included. Thirty-nine (7.5%) desmoid patients were documented of having FAP.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Frequency of CTNNB1 mutations
“CTNNB1 mutations were observed in 117 of 138 (85%) of desmoids.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Three discrete mutations in two codons of CTNNB1 exon 3 were identified: 41A (59%), 45F (33%), and 45P (8%, excluded from further analysis because of rarity).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ALTITUDES (NCT02867033) was a nationwide prospective cohort study of DF diagnosed between January 2016 and December 2020.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In 435 (84.3%) cases, there was one CTNNB1 molecular alteration: p.T41A, p.S45F, or p.S45P.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Risk factor: antecedent trauma, including prior surgery
“In 164 patients (32.7%), a trauma anteceding DT could be verified with a median lag time of 22.9 months (SD, 7.7 months; range, 9-44 months).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A prior surgical procedure was relevant in 98 patients, a blunt trauma in 35 patients, a punctuated trauma (injections, trocar) in 18 patients, and site of an implant in 10 patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The distribution of mutations in the CTNNB1 gene (codon 41 vs. 45) was similar in patients with and without a history of trauma before DT development.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Risk factors: pregnancy and estrogen
“In 220 patients, no trauma was reported (43.9%), and 58 females (11.6%) had a postpregnancy DT in the rectus abdominis muscle.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Desmoid risk in familial adenomatous polyposis: U.S. community cohort
“We conducted a retrospective cohort study of patients with pathogenic or likely pathogenic variants (PV/LPV) in APC identified through the Kaiser Permanente Northern California Electronic Database, a community-based system serving 4.6 million members.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among 328 patients with FAP, 36 (11.0%) developed DT. DT risk was highest when the APC variant was centrally located (codon 600-1600).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“All colorectal surgeries were associated with a significantly elevated DT risk: ileostomy (aOR 12.07; 2.10-69.47), subtotal colectomy with ileorectal anastomosis (aOR 9.03; 1.63-49.96), and total proctocolectomy with ileal pouch-anal anastomosis (aOR 10.98; 2.12-56.81).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In this large community-based U.S. cohort, central APC variant location, family history, and colorectal surgery were associated with increased DT risk.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Desmoid risk after risk-reducing colectomy in familial adenomatous polyposis by APC genotype and family history
“This study aimed to quantify absolute postoperative desmoid risk in FAP patients undergoing risk-reducing colectomy, stratified by APC genotype, and to assess the modifying effect of family history.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This retrospective observational study used records from a prospectively maintained registry.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among 48 high-risk patients, 30 (63%) developed desmoid, with no significant difference between colectomy and proctocolectomy (54% versus 70%, respectively; χ 2 = 1.42; P = 0.233).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among the 1213 low-risk patients, 154 (12.7%) developed desmoids, with no significant effect of surgical procedure (13.9% versus 12.1% for proctocolectomy and total/partial colectomy, respectively; χ² = 0.77; P = 0.380).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A family history of desmoid disease appears to be an important determinant of postoperative desmoid risk in FAP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Desmoid risk in a familial adenomatous polyposis cohort of 735 patients
“The medical records of 735 FAP patients were analyzed for the occurrence of desmoids.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Desmoid tumors were identified in 66 of the 735 patients (9%). The cumulative risk of developing desmoids was 14%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with a positive family history for desmoids had a significant increased risk to develop this tumor (30% vs 6.7%, P < .001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Most desmoid patients (95%) had undergone previous abdominal surgery.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Epidemiology
Incidence of Desmoid tumors
Netherlands: extra-abdominal and abdominal wall aggressive fibromatosis, 1993 to 2013
“In a population-based study in the Netherlands, we evaluated time trends for the incidence and treatment of AF.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 1134 patients were diagnosed with extra-abdominal or abdominal wall AF between January 1993 and December 2013; there were 326 men and 808 women.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence increased from 2.10 to 5.36 per million people per year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The male–female ratio showed an increasing female predominance, ranging from 68.6 % in 1993–1998 to 73.6 % in 2009–2013.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Netherlands: sporadic and familial adenomatous polyposis-related desmoid-type fibromatoses, 1999 to 2009
“For calculation of incidence rates, person-years from the general matched population were used.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The incidences of sporadic and FAP-related desmoid-type fibromatoses were 3.42 and 2,784 per million person-years, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Denmark: desmoid tumor patients treated at two sarcoma centers, 2009 to 2018
“Using Danish health registers, we studied DT patients treated at two sarcoma centers between 2009 and 2018.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 179 DT patients identified, 76% were female and the median patient age was 38 years at diagnosis (interquartile range: 31-50).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“An average annual incidence of DTs over the study period was 3.2 per 1000,000 individuals with the observed annual incidence of DTs ranging from 2.2 (2011) to 4.3 (2017) per 1000,000 individuals. No notable linear time trend in incidence was observed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Finland: historical estimates
“The reference standard on the incidence and epidemiology of AF are Finnish studies by Reitamo et al.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“An incidence of 2.4–4.3 per million people was reported in those studies, using three methods of estimation (local, regional, and national).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Literature review of incidence estimates
“The low incidence of DT (estimated 3–5 cases per million person-years) limits disease awareness.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Five European sources [24–28] providing estimates on the incidence of DT were identified in the literature.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Likewise, no epidemiological study of DT in the United States (US) was identified.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The Orphanet Report Series [26] provides an average annual incidence of 3 cases of DT per million person-years in Europe.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No estimates of incidence of DT in children are available in the literature; there is a lack of data on DT in children younger than 11 years old.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because all the epidemiological data are from European populations, a US population-based study will be necessary to compare incidence estimates between Europe and the US.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Age and sex distribution
“The epidemiological studies reveal that most DT cases appear in the age range of 20–44 years, with a female predominance, and female cases 2.2–3.9 times the number of male cases” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Onset of DT has been reported from infancy through adulthood, although it occurs most commonly between the ages of 15 and 60 years (with peak incidence between 30–40 years of age) and 2–3 times more frequently in women than men” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Company estimate: U.S. annual incidence, SpringWorks Therapeutics
Company estimate: U.S. annual incidence, Immunome
U.S. annual incidence, published estimate
“These are rare or orphan cancers with an annual incidence of 1000 patients in the United States.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The disease predominantly affects young adults and can arise in any anatomic location but favors the extremities, joints, and abdomen.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of Desmoid tumors
Literature review: no published prevalence study
“No study evaluating the prevalence of DT was identified.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Few epidemiological studies providing incidence estimates of DT were identified in the literature; all these studies were conducted in European countries, and no study provided prevalence estimates.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, no incidence or prevalence data on children are available.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Company estimate: U.S. actively managed patients from physician market research, SpringWorks Therapeutics
Company estimate: U.S. patients receiving physician care from ICD-10 claims, October 2023 to October 2024, SpringWorks Therapeutics
Company statement: prevalent pool attributed to limited effect on mortality, SpringWorks Therapeutics
Natural history, survival, and mortality
Variable clinical course: growth, stabilization, and regression
“According to estimates, approximately 10–28% of DT will resolve spontaneously without treatment (22% for extra-abdominal tumors to 28% for abdominal tumors)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“30% will cycle through progression and resolution, 50% will remain stable after diagnosis, and 10% will progress rapidly” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Active surveillance: pooled analysis of three prospective observational studies, extra-abdominal desmoid-type fibromatosis
“Three prospective observational studies (Italy, the Netherlands, and France) on active surveillance (AS) in patients with extra-abdominal desmoid-type fibromatosis support AS as a first-line approach.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients ( n = 282) with a median follow-up of 53 months (IQR, 39–63) were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The 3- and 5-year TFS rates were 67% and 66%, respectively; the 3- and 5-year crude cumulative incidences were 33% and 34% for RECIST progression, 26% and 34% for RECIST regression, and 33% and 38% for regression post-RECIST progression, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The specific mutation (S45F), larger tumor size, and extremity and trunk locations were all associated with a lower probability of spontaneous RECIST regression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study confirms that spontaneous regression occurs in a significant proportion of patients and that two-thirds are treatment free at 5 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Active surveillance: Italian prospective multicenter observational study, primary sporadic desmoid fibromatosis
“This is an Italian prospective, multicenter, observational study (NCT02547831) including patients ≥16 years with primary sporadic DF at any site.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“From 2013 to 2018, 108 consecutive patients were included (82% female); median age was 39 years; median size was 51 mm.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At 32.3-month median follow-up, 42 of 108 (39%) showed RECIST progression. Spontaneous regression was initially observed in 27 of 108 (25%), while it followed dimensional progression in another 33 of 108 (31%). PFS at 36 months was 54.5% [95% confidence interval (CI), 44.9%-66.1%].” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“TFS at 36 months was 65.9% (95% CI, 57.3%-75.9%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Active surveillance: prospective multicenter observational study of primary sporadic tumors of the extremity or abdominal or thoracic wall
“This prospective, multicenter, observational study (NCT01801176) included patients ≥18 years of age with primary sporadic DF located in an extremity or the abdominal/thoracic wall.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Between 2012 and 2015, 100 patients were enrolled.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median follow-up was 46.6 months (IQR 36.8-61.1) and the 3-year PFS was 53.4% (95% confidence interval 43.5-63.1%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Fifty-eight patients (58%) presented with spontaneous tumor regression (decrease > 0% compared with the initial size) during the first 3 months (n = 35, 35%) or after an initial progression (n = 23, 23%), of whom 26 (26%) had partial responses (PRs).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Active surveillance at all anatomic locations: United Kingdom sarcoma reference center
“Patients with a primary desmoid tumor at any anatomic location diagnosed between 1998 and 2016 were identified in a prospectively maintained database from a single sarcoma reference center in the United Kingdom.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The study identified 168 patients with a primary desmoid tumor initially managed with active surveillance.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of all the patients, 36% experienced radiologic progressive disease, 36% had stable disease, and 27% regressed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Eventually, 46% of the patients proceeded to treatment. The median time to start of treatment after initial surveillance was 31 months, whereas the median follow-up time for the patients not receiving any treatment was 40.5 months. The indications for initiation of treatment were pain (32%), progression (31%), or both (13%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Surgery compared with wait-and-see: prospective cohort of 771 cases
“We conducted a prospective study of 771 confirmed cases of DTF.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, the 2-year EFS was 56%; this value did not differ between patients undergoing an operation and those managed by the wait-and-see approach (53% versus 58%, p = 0.415).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The 2-year EFS was 66% for favourable locations (abdominal wall, intra-abdominal, breast, digestive viscera and lower limb) and 41% for unfavourable locations.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Event-free survival in the ALTITUDES nationwide prospective cohort
“ALTITUDES (NCT02867033) was a nationwide prospective cohort study of DF diagnosed between January 2016 and December 2020.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We enrolled 628 patients managed by active surveillance, surgical resection, or systemic treatment as first-line therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The first-line management was active surveillance in 352 (68.2%), surgical resection in 120 (23.3%), and systemic treatments in 44 (8.5%) patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The median follow-up period was 24.7 (range, 0.4-59.7) months. The estimated 3-year EFS rate was 66.2% [95% confidence interval (CI), 60.5%-71.2%].” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Spontaneous regression in the placebo group of a prospective trial
“Desmoid tumors can show rapid growth followed by periods of stabilization, spontaneous regression, or subsequent growth phases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Spontaneous regression is reported in up to 20% of patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Our prospective trial, in which desmoid tumors in patients who were taking placebo were evaluated, provides evidence in support of an initial period of observation in patients with newly diagnosed desmoid tumors, given that 20% of the patients in the placebo group had disease regression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Local recurrence after complete gross resection: nomogram cohort of 439 patients
“Of 439 patients undergoing complete gross resection, 100 (23%) had recurrence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Five-year local recurrence–free survival (LRFS) was 69%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In multivariate analysis, factors associated with recurrence were extremity location, young age, and large tumor size, but not margin.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Abdominal wall tumors had the best outcome (5-year LRFS 91%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Local recurrence after surgery: participant-reported data
Recurrence by tumor location and familial adenomatous polyposis status
“Tumors on extremities are believed to be locally aggressive and have recurrence rates ranging from 24% to 77%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Local recurrence rates of intra-abdominal tumors in patients with FAP are higher than those for extra-abdominal tumors and reported to be 57–86%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mortality: desmoid tumors overall
“While lacking metastatic potential, the natural history of DT is variable and ranges from an asymptomatic, indolent course to aggressive infiltration of neurovascular structures and vital organs resulting in pain, disfigurement, organ dysfunction, and— rarely—death (usually related to complications such as intestinal obstruction associated with progression of intra-abdominal tumors)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mortality after resection: nomogram cohort
“Eight patients died of disease, all after R2 resection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 44 patients were dead at last follow-up, but only 8 died of disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two patients died following intestinal transplant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mortality: Danish patients compared with a healthy matched cohort
“that has reported a 5-year mortality rate of 7 per 1000 [95% confidence interval (CI) 3–16] among Danish patients with DT as compared with 5 per 1000 (95% CI, 4–7) in a healthy matched cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The authors state that most deaths occurred in patients with FAP, though they represented only 7% of patients in the DT cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mortality: intra-abdominal desmoid tumors in familial adenomatous polyposis by stage
“Intra-abdominal desmoid tumors are one of the leading causes of death in patients with familial adenomatous polyposis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 154 patients with intra-abdominal desmoid tumors were included in the study.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Five-year survival of patients with stage I, II, III, and IV intra-abdominal desmoid tumor were 95%, 100%, 89%, and 76% respectively (P < 0.001). Severe pain/narcotic dependency, tumor size larger than 10 cm, and need for total parenteral nutrition were shown to further define survival within stages. Five-year survival rate of stage IV patient with all of the above-mentioned risk factors was only 53%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Mortality: home parenteral nutrition in familial adenomatous polyposis-associated intra-abdominal desmoids
“Intra-abdominal desmoid tumors (IADTs) are a common complication of familial adenomatous polyposis (FAP).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The need for HPN represented a strong predictor of mortality (5-year survival HPN = 72% vs non-HPN = 95%), but duration of HPN did not affect mortality.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Desmoid disease as a cause of death in familial adenomatous polyposis
“Desmoid is a major source of mortality in FAP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Desmoid tumours (DT) are one of the main causes of death in patients with familial adenomatous polyposis (FAP).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Desmoid tumors (DT) are a leading cause of morbidity and mortality in patients with familial adenomatous polyposis (FAP), yet available data on DT risk remain limited and have been largely derived from large registries or tertiary referral centers.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pathophysiology
Constitutive activation of the Wnt/β-catenin pathway
“Approximately 85–90% of sporadic cases of DT show activating mutations in the N-terminal region of CTNNB1 (all of them in exon 3)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“making β-catenin more resistant to proteolytic degradation, leading to cytoplasmic accumulation of the protein and its subsequent translocation to the nucleus.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In ~5–10% of patients, DT results from germline (i.e., in FAP) or sporadic loss-of-function mutations in the APC tumor suppressor gene.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although the molecular pathogenesis of desmoid tumors is not fully understood, dysregulation of the Wnt/β-catenin pathway and consequent transcription of prosurvival and proliferative genes likely play a critical role.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mutual exclusivity of CTNNB1 and APC mutations
Notch pathway cross-talk and overexpression
“Cross-talk between the Notch and Wnt pathways, as well as activation of the Notch pathway resulting from dysregulation of the Wnt pathway, suggest a possible therapeutic target for DT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Subsequent studies analyzed the expression of Notch pathway components in DT tissues and cell strains, and confirmed increased expression of HES1 in DT versus dermal scar tissue” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Dysregulation of the Wnt signaling pathway plays a key role in DT pathogenesis, however, as the result of crosstalk, Wnt dysregulation may lead to activation of the Notch pathway.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The overexpression of Notch pathway components in DT provides a rationale for development of pharmacologic agents targeting Notch.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Due to the role γ-secretase plays in Notch signaling through cleavage of the Notch intracellular domain (with subsequent translocation to the nucleus to activate gene transcription), γ-secretase inhibitors (GSIs) have emerged as a potential treatment for DT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CTNNB1 genotype and tumor behavior
“Five-year recurrence-free survival was significantly poorer in 45F-mutated desmoids (23%, P < 0.0001) versus either 41A (57%) or nonmutated tumors (65%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“DF harboring p.S45F was significantly associated with male sex (P = 0.03), non-abdominal wall sites (P = 0.05), pain (P = 0.007), and large tumor size (P = 0.025). CTNNB1 p.S45F mutation was not significantly associated with EFS, either in univariate (HR, 1.06; 95% CI, 0.65-1.73; P = 0.81) or in multivariate analysis (HR, 0.91; 95% CI, 0.55-1.49; P = 0.71).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Diagnosis
Histopathologic confirmation by core needle biopsy
“The histopathologic confirmation of DF is mandatory before initiating treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A diagnosis of DF can be readily established on core biopsies using 14G or 16G needles, while neither incisional nor excisional biopsy is recommended as the initial diagnostic modality.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Expert soft tissue pathology review
CTNNB1 mutational analysis: guideline recommendation
CTNNB1 testing and screening for familial adenomatous polyposis in 226 patients
“226 patients were identified and 67% (n = 152) were female.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Colonoscopy was requested in 65 patients (28.8% of all cases) and was completed in forty-six (20.4%). Molecular testing of CTNNB1 testing was requested in 35 cases (15.5%). APC germline test was requested in 12 cases. Four patients in our cohort had an FAP-associated DF.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“CTNNB1 molecular testing should be performed in all cases of newly diagnosed DF. Negative CTNNB1 results, alongside clinical assessment, should prompt APC testing and/or colonoscopy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Referral for colonoscopy by tumor location and age
“In conclusion, patients with desmoid-type fibromatoses are at risk of underlying FAP. Especially cases with desmoid localization intra-abdominal or in the abdominal wall, and all patients younger than 60 years, have a substantial increased risk and should be referred for colonoscopy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
CTNNB1 sequencing in β-catenin-negative desmoid fibromatosis
“A single-center, large retrospective analysis of 780 patients with DF was performed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“77.3% of DF cases exhibited nuclear β-catenin positivity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Molecular analysis revealed that 74.1% of β-catenin negative cases harbored CTNNB1 mutations, primarily at codon 41 (p.T41A).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Notably, β-catenin IHC showed higher positivity in resected specimens (79.7%) compared to biopsies (62.0%), whereas CTNNB1 mutational detection was higher in biopsies (93.5%) than resections (76.8%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
CTNNB1 testing documented at a U.S. academic center
“Therefore, we aimed to characterize the patient journey in DTs from diagnosis to treatment at an academic center in the United States.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A much smaller proportion of patients had documentation of CTNNB1 testing ( n = 10, 6.7%), including seven with CTNNB1 mutation (4.7%) and three who were demonstrated to have the wild-type, nonmutated variant, which results in production of normal β-catenin (2%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Diagnostic methods, such as CTNNB1 testing, may also shorten the diagnostic journey.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Imaging: magnetic resonance imaging for diagnosis, local staging, and follow-up
“MRI is the mainstay of imaging in DF and can be used for diagnosis, local staging and follow-up” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The lack of radiation exposure makes targeted MRI ideal for follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Histopathological diagnosis is mandatory, and evaluation is guided with imaging studies ranging from ultrasound, computed tomography or magnetic resonance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ultrasound (US) serves as the initial evaluation especially for tumors in the extremities or abdominal wall.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Its appearance depends on the cellular composition where more fibrotic areas, with a greater amount of collagen, show a low signal intensity in T2 with moderate contrast enhancement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Response assessment: RECIST and magnetic resonance imaging signal
Response assessment: T2-weighted signal intensity and tumor volume in the RINGSIDE phase 2 study
Response assessment: quantitative T2 mapping
“However, the primary imaging endpoints based on RECIST1.1 used in these studies are determined only by changes in maximum tumor diameter.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Analysis of T2 relaxation time maps of DF may offer a feasible quantitative biomarker for assessing the extent of response to treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Misdiagnosis and time to diagnosis: participant-reported data
“A total of 162 participants (41%, 162/399) reported a prior misdiagnosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median age at the first sign or symptom of DT was 32 years, and the average time from the first sign or symptom to confirmed DT diagnosis was 4 years ( n = 292; median = 1 year).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most reported differential diagnoses (70%, 113/162) were benign tumors or other conditions, including muscle injury, lipoma, colon polyps, postoperative scars, early-onset arthritis, hernia, and Baker’s cyst.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among 126 participants who reported a prior misdiagnosis and history of surgery for DT, 46% (58/126) reported having received surgery before a definitive DT diagnosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Misdiagnosis before confirmed diagnosis: U.S. academic center
“Therefore, we aimed to characterize the patient journey in DTs from diagnosis to treatment at an academic center in the United States.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 43 patients (29.1%) potentially had a misdiagnosis prior to a final confirmed diagnosis of DT based on tissue histology” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most common misdiagnoses included other benign tumors ( n = 31, 20.3%), low-grade sarcomas ( n = 11, 7.2%), nodular fasciitis ( n = 4, 2.6%), and procedure-related scars ( n = 3, 2%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Histologic misdiagnosis in published series
“Based on pathologic similarities with other myofibroblastic diseases (e.g., sarcoma, gastrointestinal stromal tumor, nodular fasciitis, leiomyoma) and the low incidence of DT, 30–40% of DT cases are reported to be misdiagnosed following histologic analysis” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A French nationwide survey demonstrated that one-third of DT are misdiagnosed (the most challenging differential diagnoses are nodular fasciitis and low-grade fibromyxoid sarcoma)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinical presentation - signs and symptoms
Variability of presentation: asymptomatic to symptomatic tumors
Pain: tumor pain
“Pain was the most common reported symptom (57.4%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“DT-related symptoms that were most documented in the clinical notes were tumor pain ( n = 85, 57.4%), fullness ( n = 23, 15.5%), loss of function ( n = 22, 14.9%), and paresthesia ( n = 17, 11.5%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Neurological symptoms: nerve pain and paresthesia
| Symptom elicited in concept elicitation interviews (n = 31) | Frequency of mentions | Median disturbance rating |
|---|---|---|
| Nerve pain (localized/radiating) | “22”View highlighted excerpt for this quote | “6.00”View highlighted excerpt for this quote |
| Muscle pain (localized/radiating) | “20”View highlighted excerpt for this quote | “6.75”View highlighted excerpt for this quote |
“Symptomatic disease was ascertained based on documentation of symptoms, including tumor-related pain, paresthesia, fatigue, swelling, muscle weakness, loss of function (such as difficulty in moving limbs or walking), nausea, and fullness.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Physical function: decreased range of motion and loss of mobility
“Desmoid tumors (or aggressive fibromatosis) are locally infiltrative connective-tissue tumors that can arise in any anatomic location; they can be asymptomatic, or they can result in pain, deformity, swelling, and loss of mobility and/or threaten visceral organs with bowel perforation, hydronephrosis, neurovascular damage, and other complications.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Symptom elicited in concept elicitation interviews (n = 31) | Frequency of mentions | Median disturbance rating |
|---|---|---|
| Decreased range of motion | “21”View highlighted excerpt for this quote | “4.00”View highlighted excerpt for this quote |
| Stiffness | “10”View highlighted excerpt for this quote | “3.00”View highlighted excerpt for this quote |
“Those with the current presence of DT at the time of survey completion reported significantly worse pain (dull pain, shooting pain), swelling around the tumor, and difficulty moving body areas near the tumor (compared with those without the current presence of DT).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Appearance: disfigurement and swelling
| Symptom elicited in concept elicitation interviews (n = 31) | Frequency of mentions | Median disturbance rating |
|---|---|---|
| Disfigurement/altered appearance | “25”View highlighted excerpt for this quote | “5.00”View highlighted excerpt for this quote |
| Swelling | “6”View highlighted excerpt for this quote | “5.00”View highlighted excerpt for this quote |
Fatigue and sleep disturbance
“In addition to pain and functional impairments, health care workers should also address fatigue, insomnia, anxiety, fear, and body dysmorphia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Symptom or impact elicited in concept elicitation interviews (n = 31) | Frequency of mentions | Median disturbance rating |
|---|---|---|
| Fatigue | “20”View highlighted excerpt for this quote | “5.00”View highlighted excerpt for this quote |
| Lack of energy | “15”View highlighted excerpt for this quote | “5.50”View highlighted excerpt for this quote |
| Difficulty sleeping | “24”View highlighted excerpt for this quote | “7.50”View highlighted excerpt for this quote |
Intra-abdominal symptoms: nausea, early satiety, bowel obstruction, perforation, and hydronephrosis
“Depending on its location, patients can present with pain, a loss of range of movement or immobility, bowel obstructions and/or perforations, hydronephrosis, and a host of other symptoms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As expected, the symptoms and impacts preliminarily show variation by anatomical location, as seen with abdominal desmoids, which cause nausea and early satiety.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The HPN group was more likely to have advanced-stage disease and significantly higher incidence of chronic abdominal pain, narcotic dependency, bowel obstruction, ureteral obstruction, deep vein thrombosis, pulmonary embolism, fistulae, and sepsis (P < .05).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Psychological symptoms: fear, anxiety, and depression
| Impact elicited in concept elicitation interviews (n = 31) | Frequency of mentions | Median disturbance rating |
|---|---|---|
| Fear | “26”View highlighted excerpt for this quote | “6.50”View highlighted excerpt for this quote |
| Anxiety | “22”View highlighted excerpt for this quote | “6.75”View highlighted excerpt for this quote |
| Depression | “20”View highlighted excerpt for this quote | “8.00”View highlighted excerpt for this quote |
| Altered body image/function | “12”View highlighted excerpt for this quote | “4.75”View highlighted excerpt for this quote |
Long-term morbidity
Functional deficits and disfigurement after surgery
“Although surgery is a potential treatment option, complete excision with negative margins is not often possible, the postsurgery recurrence rate is high, and surgery can result in disfigurement and/or loss of function.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Tumors in the extremities have the highest risk of recurrence (30%-90%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Although effective in specific cases, surgery may be associated with poor long-term functional outcomes and higher economic costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Long-term use of analgesics and other medications
“A total of 56% of DT patients used chemotherapeutic agents, tyrosine kinase inhibitors, NSAIDs, opioids, antidepressants, or steroids at some point during the three years before their DT diagnoses. In contrast, 70% of surgically treated and 63% of non-surgically treated patients used one of these drugs in the subsequent three years, including NSAIDs (45% surgical vs. 33% non-surgical), opioids (39% surgical vs. 27% non-surgical), and steroids (22% surgical vs. 18% non-surgical).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
| Medication for desmoid tumor symptom management | Overall (N = 322), n (%) | Current presence of a desmoid tumor (n = 225), n (%) | No current desmoid tumor (n = 97), n (%) |
|---|---|---|---|
| NSAIDs | “151 (47)”View highlighted excerpt for this quote | “103 (46)”View highlighted excerpt for this quote | “48 (49)”View highlighted excerpt for this quote |
| Opioids | “61 (19)”View highlighted excerpt for this quote | “45 (20)”View highlighted excerpt for this quote | “16 (16)”View highlighted excerpt for this quote |
| Antidepressants | “60 (19)”View highlighted excerpt for this quote | “41 (18)”View highlighted excerpt for this quote | “19 (20)”View highlighted excerpt for this quote |
| Anticonvulsants | “36 (11)”View highlighted excerpt for this quote | “26 (12)”View highlighted excerpt for this quote | “10 (10)”View highlighted excerpt for this quote |
Chronic pain and dependency on analgesics
Persistent symptoms with current disease
“Participants with the presence of DT at survey completion reported significantly worse scores for pain, extra-abdominal symptoms, fatigue, physical functioning, and sleep in comparison to those without the current presence of a DT ( P < 0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Intestinal failure and home parenteral nutrition in familial adenomatous polyposis-associated intra-abdominal desmoids
“Intra-abdominal desmoid tumors (IADTs) are a common complication of familial adenomatous polyposis (FAP).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Medical and surgical treatments may be ineffective in preventing complications, which can cause intestinal failure.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“One hundred fifty-four patients were included and divided into 2 groups: HPN (n = 41, 26.6%) and non-HPN (n = 113, 73.4%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“HPN, although a life-saving treatment, is an independent poor prognostic factor associated with high morbidity and mortality.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Constraints on colorectal surgery in familial adenomatous polyposis
Burden of Desmoid tumors
Humanistic burden and health-related quality of life
GODDESS development: concept elicitation and cognitive interviews
“CE interviews with desmoid patients (n = 31) helped to identify salient concepts and led to a draft scale that included symptom and impact scales. Cognitive interviews were completed with additional patients (n = 15) across 3 phases. Patient input was used to refine instructions, revise and/or remove items, and modify the response scale. This resulted in an 11-item symptom scale and a 17-item impact scale.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This is the first disease-specific PRO instrument developed for desmoid tumors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thirty-one patients (mean age, 44 years; standard deviation, 13 years; 77% female) completed the CE phase, and the demographics are described in Table 1. The majority of the patients had at least a college degree (71%) and were symptomatic (84%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 33 unique symptoms were identified (Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Disease impacts reported in GODDESS concept elicitation interviews
| Impact | Frequency of mentions (n = 31) | Median disturbance rating (0 to 10) |
|---|---|---|
| Fear | “26”View highlighted excerpt for this quote | “6.50”View highlighted excerpt for this quote |
| Difficulty sleeping | “24”View highlighted excerpt for this quote | “7.50”View highlighted excerpt for this quote |
| Anxiety | “22”View highlighted excerpt for this quote | “6.75”View highlighted excerpt for this quote |
| Inability to do daily activities | “20”View highlighted excerpt for this quote | “6.75”View highlighted excerpt for this quote |
| Depression | “20”View highlighted excerpt for this quote | “8.00”View highlighted excerpt for this quote |
| Isolation | “17”View highlighted excerpt for this quote | “7.00”View highlighted excerpt for this quote |
| Financial difficulties | “16”View highlighted excerpt for this quote | “8.00”View highlighted excerpt for this quote |
| Hopelessness | “14”View highlighted excerpt for this quote | “8.50”View highlighted excerpt for this quote |
| Inability to do work | “14”View highlighted excerpt for this quote | “6.75”View highlighted excerpt for this quote |
GODDESS psychometric properties and meaningful change thresholds in the DeFi trial
“DeFi participants (N = 142) had a median age of 34 years (range: 18–76) and were mostly female (64.8%), with extra-abdominal (76.8%) or intra-abdominal tumors (23.2%). The GODDESS© symptom/impact scales showed internal consistency at baseline, cycles 4 and 7 (Cronbach’s α > 0.70) and test–retest reliability (intra-class correlation coefficient > 0.85).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For the total symptom score, a 1.30-point decrease was estimated as the within-person MCT and a 1.00-point decrease as the between-group MCT. For the physical functioning impact score, estimated within- and between-group MCTs were 0.60-point and 0.50-point decreases, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Desmoid Tumor Research Foundation natural history study, 2017 to 2023
“Surveys were completed by 399 participants between September 2017 and August 2023. The median age of participants was 38 years; most were female (72%, 288/399), White (84%, 334/399), or resided in North America (86%, 345/399).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants with the presence of DT at survey completion reported significantly worse scores for pain, extra-abdominal symptoms, fatigue, physical functioning, and sleep in comparison to those without the current presence of a DT (P < 0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The overall mean Total Symptom Score for all participants was 4.1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The symptoms and impact of DT in a joint/extremity were reported to be significantly worse for the DTSS Total Symptom Score, DTSS Pain domain, and the DTIS Physical Functioning domain compared with other DT locations (all P < 0.05; Fig. 7a-c).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Conversely, regardless of the current presence of DT, participants reported similar mean scores (P > 0.05) for the DTIS Emotional Impact domain (4.4 with current DT vs. 3.9 without current DT) and all Emotional Impact domain item scores, including Fear of Desmoid Tumor Growth/Recurrence (5.8 vs. 5.2), Anger (3.4 vs. 3.1), Anxiety (4.5 vs. 4.0), and Frustration (4.8 vs. 4.0), except Hopelessness (3.7 vs. 2.7; P = 0.007; data not shown).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Physical symptom burden clusters in the United Kingdom and the Netherlands
“Desmoid‐type fibromatosis patients from the United Kingdom and the Netherlands received cross‐sectional questionnaires on HRQoL (EORTC QLQ‐C30), DTF‐specific HRQoL (DTF‐QoL) and healthcare utilisation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among 235 DTF patients, four symptom burden clusters were identified, with low symptom burden (24%), intermediate symptom burden‐low pain (20%), intermediate symptom burden‐high pain (25%) and high symptom burden (31%). DTF patients with high symptom burden had clinically relevant lower HRQoL scores compared to patients with low and intermediate symptom burden (p < 0.001)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
DTF-QoL development in the United Kingdom and the Netherlands
“The aim of this study was to pre-test the psychometric properties of the DTF-QoL by administering it together with the EORTC Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) to 236 DTF patients from the United Kingdom and the Netherlands.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ninety-six items were selected, conceptualised into three symptom scales, eleven disease-impact scales and six single items, together forming the final DTF-QoL.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Characteristics associated with poorer disease-specific quality of life
“A total of 235 DTF patients completed the questionnaires. Female patients, patients with more than two comorbidities, or patients who received treatment other than only active surveillance (AS) or surgery scored significantly worse on the subscales of both the EORTC QLQ-C30 and DTF-QoL.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Quality of life, anxiety, and depression compared with healthy controls
“Two hundred four subjects (102 DTF patients and 102 healthy controls) were recruited. The median age of DTF patients at recruitment into the study was 31 years (IQR, 25-37 years).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mean global health status in DTF patients was 65.58 ± 22.64, significantly lower than healthy controls. Similarly, DTF patients scored low on all functional scales except cognitive functioning. The symptom scale showed a significantly higher symptom burden of fatigue, pain, insomnia, and financial difficulties. Anxiety and depression was observed in 39.22% and 50% of DTF patients respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Focus groups and interviews at a United Kingdom sarcoma unit
“Twenty-seven DF patients were purposively sampled from The Royal Marsden Hospital. Two focus groups and 13 interviews (males 12, females 15; mean age at study 39.5 years) explored health-related quality of life issues and experiences of healthcare.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pain was the most debilitating symptom and dependency on painkillers was a significant concern. Functional limitation and restricted mobility frequently affected daily activities.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“low on all functioning scales (physical 74.4; role 55.8; social 52.8; cognitive 70.1; and emotional 56.9) and global QoL scale (56.9) of the EORTC QLQ-C30 and exceptionally high on the symptom scales pain (59.0), insomnia (56.9), fatigue (53.6) and financial difficulties (31.9).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Literature review and focus groups on quality of life issues in sporadic desmoid-type fibromatosis
“The search strategy identified thirteen articles reporting HRQL measures using a wide variety of cancer-specific HRQL tools, functional scores, symptom scales (e.g. NRS), and single-item outcomes (e.g. pain and functional impairment). No DTF-specific HRQL tool was found. Qualitative analysis of three focus groups (6 males, 9 females) showed that participants emphasised the negative impact of DTF and/or its treatment on several HRQL domains.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Anxiety and depression compared with malignant sarcoma
“Despite its limited impact on survival, patients with DT may have anxiety and depression levels commensurate with those associated with malignant sarcomas.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Interestingly, investigators found that anxiety and depression in patients with DT were significantly (P = 0.01) greater in patients with abdominal wall DT than in the sarcoma group, and among patients with DT outside of the abdominal wall, distress levels were equivalent to those of patients with malignant sarcomas.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pain at diagnosis in the ALTITUDES cohort
“Overall, 382 patients were included in the current study (median age: 40.2 years; 117 men). The prevalence of pain was 36%, without significant difference according to first-line treatment (P = .18).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Pain at baseline was significantly associated with poor quality of life (P < .001), depression (P = .02), lower performance status (P = .03) and functional impairment (P = .001)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pain burden survey by the French patient advocacy group SOS Desmoid
Pain and its consequences: systematic literature review
“Patients with DT experience a high symptom burden: up to 63% of patients experience chronic pain, which leads to sleep disturbance (73% of cases), irritability (46% of cases), and anxiety/depression (15% of cases).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Patient and clinical expert testimony to NICE
Health state utility values in the NICE appraisal of nirogacestat
Economic burden and healthcare resource utilization
Direct and indirect costs: systematic literature review
“No studies evaluating direct or indirect costs of patients with DT were identified in the literature.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No monetary costs from loss of employment and hospital travel expenses were reported in these studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Danish registry healthcare resource utilization and medication use, 2009 to 2018
“Using Danish health registers, we studied DT patients treated at two sarcoma centers between 2009 and 2018. For each patient, ten persons from the general population were randomly matched on birth year, sex, and region of residence.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 56% of DT patients used chemotherapeutic agents, tyrosine kinase inhibitors, NSAIDs, opioids, antidepressants, or steroids at some point during the three years before their DT diagnoses. In contrast, 70% of surgically treated and 63% of non-surgically treated patients used one of these drugs in the subsequent three years, including NSAIDs (45% surgical vs. 33% non-surgical), opioids (39% surgical vs. 27% non-surgical), and steroids (22% surgical vs. 18% non-surgical). The average number of inpatient and outpatient visits, days of hospitalization, and additional surgical procedures were higher among DT patients than the comparison cohort.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Danish registry visits and hospital days within 3 years of diagnosis
“Healthcare resource utilization of patients with DT was substantially higher than that in the comparison cohort, both 1 and 3 years after the diagnosis. Within 3 years after the index date, patients with DT had, on average, 1 inpatient and 7.1 outpatient visits as well as 7.5 days in the hospital compared with an average of 0.8 inpatient and 0.1 outpatient visits and 0.8 days in the hospital in the comparison cohort. The median duration of hospitalization for DT-related surgery was 5 days (interquartile range, 3–7).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States academic center resource utilization, 2011 to 2023
“A retrospective cohort study was conducted at the University of Utah Health network. Eligible patients were diagnosed with DTs between January 1, 2011, and July 31, 2023, were ≥18 years old at diagnosis, and had ≥2 DT-related encounters.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Healthcare resource utilization was quantified using administrative claims.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“88.5% of patients had at least one outpatient visit related to DTs, with an average number of 2.4 visits per patient per year. In contrast, only a small proportion of patients had emergency visits related to DTs (n = 5, 3.4%). Approximately one fifths of patients (n = 30, 20.3%) required hospitalizations related to DTs with a median length of stay per year of 4.5 days (IQR: 3–8, range: 1–35).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although there was no increase in the proportion of patients who engaged outpatient services, the median number of outpatient visits almost tripled in the event of symptomatic disease (7.2 per patient per year) and doubled during active disease (4.7 per patient per year).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Healthcare use by physical symptom burden in the United Kingdom and the Netherlands
“DTF patients with high symptom burden had clinically relevant lower HRQoL scores compared to patients with low and intermediate symptom burden (p < 0.001) and reported more general and DTF‐related visits to their general practitioner compared to the low symptom burden cluster (p < 0.01). In the multivariate analyses, symptom burden was independently associated with both HRQoL and healthcare utilisation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“DTF patients in the intermediate symptom burden–high pain and high symptom burden clusters were more frequently receiving additional care, mostly from a physiotherapist or psychologist (Table S4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Medications for symptom management in the Desmoid Tumor Research Foundation natural history study
Monitoring frequency in the Desmoid Tumor Research Foundation natural history study
“As expected, a higher proportion of participants (77%, 181/235) with a current DT were monitored (regular clinic visits and radiologic assessment, including computed tomography and magnetic resonance imaging) at least every 6 months relative to those without (54%, 49/91).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Work loss attributed to pain: SOS Desmoid survey as summarized in a systematic review
“Studies [4, 41] assessing the impact of DT on employment and job productivity have reported that patients experience a negative impact on their employment due to their disease and find it frustrating being unable to work (26% stopped working and 10% worked part- time; see Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pain-related work disturbances included 17 patients (26%) who stopped working altogether and 7 (10%) who worked only part time due to pain” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Employment and financial difficulty at a United Kingdom sarcoma unit
“DF patients experienced changes to their employment due to their disease and found it frustrating being unable to work and wanting to feel ‘normal’. Some patients felt discriminated due to enforced sick leave, which was demoralising and led to loss of progression within their job role. In addition, financial difficulty resulting from loss of employment and hospital travel expenses was a significant concern for several patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Interruption of work after treatment: Dutch focus groups
“Participants reported that DTF had influenced their working life, as they had to stop working temporarily after treatment. This period ranges from a couple of weeks to two years and in one case not being able to work at all.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic burden of surgery: literature review
“Since economic data related to DT surgery is lacking, reviews of surgery costs in soft-tissue sarcomas and of general costs of amputations were conducted.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Tumors in the extremities have the highest risk of recurrence (30%-90%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Although effective in specific cases, surgery may be associated with poor long-term functional outcomes and higher economic costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cost of 10-year active surveillance in NHS Scotland
“To estimate the direct costs associated with active surveillance (AS), we adopted a conservative costing approach based on current NHS tariffs, focusing on imaging and clinic visit expenses. The study assumes a 10-year follow-up period. The current cost per MRI was £130. Based on current NHS tariffs, each appointment costs approximately £233.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At a cost of roughly £130 per MRI scan, this translates to a total imaging cost of £2340 per patient. Assuming an equal number of clinic visits throughout the follow-up period, with each consultant-led clinic appointment costing £233 as per current NHS Scotland figures, the total combined cost of imaging and appointments exceeds £6500 per patient.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cost per outcome of sorafenib at Medicare Part D rates
“Current Medicare Part D rates for sorafenib were utilized (dose 400 mg/day, cost $309/day).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At one year, sorafenib was associated with a 43% absolute risk reduction (ARR) of CAR progression and number-needed-to-treat (NNT) of 2.3 patients/year, costing $259,406. At two years, ARR was 48% and NNT of 2.1 patients/year, costing $473,697. When evaluating only patients with RECIST defined radiologic progression, sorafenib patients experienced ARR of 13.9% with NNT 7.2 and estimated costs of $812,052 at one year.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
German statutory health insurance target population and annual treatment cost of nirogacestat
Basis of the German patient numbers and treatment cost calculation for nirogacestat
Nirogacestat list price in England
Resource use assumptions and intra-abdominal care needs in the NICE appraisal of nirogacestat
Economic impact of Desmoid tumors on families
Age and sex distribution: women of childbearing and working age
“Additionally, the burden of DT is disproportionately borne by women of childbearing and working age, and because it is associated with low mortality and a relatively young patient population, it typically continues for decades.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Impact on careers, family, and carers: NICE committee discussion
Parental role and dependence on family members
“DF patients also felt that their parental role was affected including difficulty breastfeeding, playing games with their children and depending on their partner or parent for childcare.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Financial strain due to lost productivity and medical costs, including travelling costs to the hospital can lead to dependence on family members and have an adverse effect on patients’ social relationships.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Family planning: Dutch focus groups
“One participant reported that DTF restricted her from having another child, which had a major impact on her family.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Another participant reported the feeling that he missed out on starting a family because of extensive treatments which started at a young age.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Family-related impacts reported in GODDESS concept elicitation interviews
| Impact | Frequency of mentions (n = 31) | Median disturbance rating (0 to 10) |
|---|---|---|
| Concern for other family members | “20”View highlighted excerpt for this quote | “6.25”View highlighted excerpt for this quote |
| Worry over becoming pregnant | “7”View highlighted excerpt for this quote | “6.00”View highlighted excerpt for this quote |
Pregnancy and desmoid fibromatosis: international multicenter study
“This international, multicenter, retrospective observational study included data from 157 women with DF, contributing 177 pregnancies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among 177 pregnancies, Group A exhibited the highest rates of DF progression (68.7 % during pregnancy, 40.6 % postpartum), while Groups B and C had lower progression rates (9.5 % during pregnancy, 8.3 % postpartum). Active treatment was required in 5.6 % of cases. Spontaneous regression occurred in 23.7 % of pregnancies, particularly following progression. Obstetric complications were comparable to those in the general population.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Individualized counseling is essential for managing risks of progression and recurrence, supporting informed fertility decisions. Referral to specialized centers is recommended to optimize DF management during family planning and pregnancy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pregnancy-related desmoid fibromatosis: four sarcoma centers
“Ninety-two women were included. Forty-four women (48%) had pregnancy-related DF (A + B), whereas 48 (52%) had a history of DF before conception (C + D).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“DF does not increase obstetric risk, and it should not be a contraindication to future pregnancy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pregnancy-associated desmoid fibromatosis: Dutch multicenter study
“Overall, 62 patients were included. The most common locations were abdominal wall (74%), pelvis (10%) and extremities (10%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Ten patients (16%) were diagnosed during pregnancy, while the remainder were diagnosed after pregnancy with a median time from delivery to diagnosis of 19 months (1-60). The frontline management was AS in 38 patients (61%) of whom 12 (33%) developed progressive disease and surgery in 23 patients (37%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Recent pregnancy and risk of progression or relapse in the ALTITUDES cohort
“A total of 242 patients (median age, 34.7 years) were included in the present study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pregnancy occurred within 24 months before, at the time of, and after DF diagnosis in 33%, 5%, and 10% of the cases, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After adjusting for DF location, tumor size, front-line treatment strategy, and hormonal contraception, we observed an increased risk of events occurring at 24 months after pregnancy [hazard ratio (HR) = 2.09, P = 0.018].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fertility considerations across treatment options: NICE committee discussion
Fertility preservation in familial adenomatous polyposis-associated desmoid tumours
“The study included women with FAP-associated desmoid tumours who underwent fertility treatments at the authors' tertiary medical centre between the years 2011 and 2021.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 17 women were identified suitable for this study. A total of 117 mature oocytes were vitrified for fertility preservation and 106 embryos were submitted to PGT-M. One patient returned to claim her cryopreserved oocytes, and five patients who underwent PGT-M embryo transfer reported three live births.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Ovarian stimulation for women with desmoid tumours was characterized in some patients with an acceleration in tumour growth, regardless of the use of aromatase inhibitors.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Oocyte cryopreservation before systemic therapy in young adults
“With a peak incidence in young adulthood, desmoid tumors (DTs) often cause pain, loss of function, and diminished quality of life.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Eleven young adult (YA) patients with DT who received nirogacestat were identified for the study. The median patient age was 26 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Out of nine female patients, two elected to undergo oocyte cryopreservation prior to starting therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Treatment schedule for children: Pediatric Oncology Group phase 2 study
“To determine the efficacy and safety of using vinblastine (Vbl) and methotrexate (Mtx) in children with desmoid-type fibromatosis that is recurrent or not amenable to treatment with radiation or surgery.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients were treated using Vbl (5 mg/m2/dose) and Mtx (30 mg/m2/dose), both administered by intravenous injection weekly for 26 weeks and every other week for an additional 26 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of diagnostic testing
Cost of centralized histological review in the French RRePS network
“A decision tree was used to assess the expected costs of two strategies of disease management: one based on revised diagnoses after centralized histological review (option 1), the other on diagnoses without centralized review (option 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The time horizon was 12 months and the perspective of the French National Health Insurance (NHI) was retained. Costs were expressed in Euros for 2013.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 2,425 patients were included. Three hundred forty-one patients (14%) had received discordant diagnoses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The probability of discordance was higher for a final diagnosis of desmoid tumors when compared to liposarcomas (odds ratio = 5.1; 95%CI [2.6–10.4]). The expected costs per patient for the base-case analysis (low- and high-case scenarios) amounted to €8,791 (€7,033 and €10,549, respectively) for option 1 and €8,904 (€7,057 and €10,750, respectively) for option 2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Centralized histological reviews are likely to provide cost-savings for the French NHI.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Molecular testing and unit costs of review in the French RRePS network
“Each center reviewed cases from the corresponding area using systematic molecular testing for every tumor that was suspected to have a specific genomic abnormality (e.g., KIT and PDGFRA mutations for GIST, CTNNB1 mutation for desmoid tumors, specific translocations for sarcomas with a recurrent translocation, and MDM2/CDK4 amplifications for atypical/well-differentiated and dedifferentiated liposarcomas).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“RRePS network organization (per patient)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“€103” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Histological review (per patient)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“€228” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Concordance and 12-month management cost by initial and final diagnosis involving desmoid tumors
CTNNB1 and APC testing uptake at a United Kingdom specialist center
“226 patients were identified and 67% (n = 152) were female. Median age at diagnosis was 37.5 (range 2-81) years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Colonoscopy was requested in 65 patients (28.8% of all cases) and was completed in forty-six (20.4%). Molecular testing of CTNNB1 testing was requested in 35 cases (15.5%). APC germline test was requested in 12 cases. Four patients in our cohort had an FAP-associated DF.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“CTNNB1 molecular testing should be performed in all cases of newly diagnosed DF. Negative CTNNB1 results, alongside clinical assessment, should prompt APC testing and/or colonoscopy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
CTNNB1 testing uptake, cost, and reimbursement at a United States academic center
“A much smaller proportion of patients had documentation of CTNNB1 testing (n = 10, 6.7%), including seven with CTNNB1 mutation (4.7%) and three who were demonstrated to have the wild-type, nonmutated variant, which results in production of normal β-catenin (2%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Therefore, CTNNB1 testing is useful to diagnose or rule out DTs when APC mutations are not detected or morphologic features of DTs are inconclusive in the biopsy specimen (29). Notably, the proportion of patients with CTNNB1 testing was low in our participant cohort, potentially due to cost and reimbursement issues.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Resource utilization before diagnosis among patients with potential misdiagnosis
“A total of 43 patients (29.1%) potentially had a misdiagnosis prior to a final confirmed diagnosis of DT based on tissue histology (Table 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the first year prior to DT diagnosis, healthcare resource utilization was higher among patients with prior misdiagnoses, with a higher proportion of patients requiring outpatient visits (65.1% vs. 30.3%, P < 0.001), emergency room visits (14% vs. 2.6%, P = 0.03), and hospitalization (25.6% vs. 2.6%, P < 0.001; Table 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Surgery before a definitive diagnosis in the Desmoid Tumor Research Foundation natural history study
“A total of 162 participants (41%, 162/399) reported a prior misdiagnosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among 126 participants who reported a prior misdiagnosis and history of surgery for DT, 46% (58/126) reported having received surgery before a definitive DT diagnosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Misdiagnosis during initial work-up and its consequences
“misdiagnosis rates for DT may be as high as 30–40% during an initial work-up,” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“which can result in additional treatments (eg, surgical excision) and delays for patients in receiving appropriate disease management.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CTNNB1 genotyping and germline APC testing in children
“Forty-four desmoids in pediatric patients were identified in the pathology files of 2 large referral centers (1995-2009).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“CTNNB1 mutations were observed in 29 of 44 (66%) desmoids, with 3 mutations identified: T41A (64%), S45F (29%), and S45P (7%). Germline APC mutations were present in 7 (16%) desmoid patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Given the implications, genetic counseling is recommended for children diagnosed with desmoid tumors lacking CTNNB1 mutations because this population is enriched for FAP patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Approaches to treatment
Current treatment options and standard of care
Active surveillance
Active surveillance as the primary approach
Monitoring schedule and threshold for starting active treatment
Referral to experienced centers during active surveillance
Consensus update of June 2023: shift toward less-invasive management
“To update the 2020 global evidence-based consensus guideline on the management of patients with DT, the Desmoid Tumor Working Group convened a 1-day consensus meeting in Milan, Italy, on June 30, 2023” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Previously, surgery was the standard primary treatment modality; however, within the past decade, a paradigm shift toward less-invasive management has been introduced and an effort to harmonize the strategy among clinicians has been made.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Selection of the appropriate strategy should consider DT-related symptoms, associated risks, tumor location, disease morbidities, available treatment options, and preferences of individual patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Watch and wait as the front-line approach for newly diagnosed patients
“Immediate surgery is no more the standard treatment of DF.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There is clear consensus that a conservative watch and wait strategy should be the front-line approach to newly diagnosed patients, irrespective of existing pain or other clinical symptoms, offering a way to understand the behavior of the disease and tailor next treatment steps.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The time interval for a watch and wait approach could be 1–2 years and patients should be closely followed, preferably using contrast enhanced MRI.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Active surveillance in line with Desmoid Tumour Working Group and NCCN recommendations
Pooled analysis of three prospective observational studies: treatment-free survival and progression
“In this pooled analysis from three prospective observational studies on patients with extra-abdominal desmoid-type fibromatosis, we confirm that spontaneous regression occurs in a significant proportion of patients and that two-thirds are treatment free at 5 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients (n = 282) with a median follow-up of 53 months (IQR, 39–63) were included. The 3- and 5-year TFS rates were 67% and 66%, respectively; the 3- and 5-year crude cumulative incidences were 33% and 34% for RECIST progression, 26% and 34% for RECIST regression, and 33% and 38% for regression post-RECIST progression, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The 3- and 5-year PFS rates (95% CI) were 54% (48%–60%) and 51% (45%–58%), respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In total, 93 of 282 (33.0%) patients received AT after initial AS, of which 45 (48.4%) patients received AT after RECIST progression, and 48 (54.6%) patients received AT after symptomatic progression alone.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The specific mutation (S45F), larger tumor size, and extremity and trunk locations were all associated with a lower probability of spontaneous RECIST regression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prospective multicenter observational study of peripheral primary sporadic tumors
“This prospective, multicenter, observational study (NCT01801176) included patients ≥18 years of age with primary sporadic DF located in an extremity or the abdominal/thoracic wall.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Between 2012 and 2015, 100 patients were enrolled.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median follow-up was 46.6 months (IQR 36.8-61.1) and the 3-year PFS was 53.4% (95% confidence interval 43.5-63.1%). At progression (48 patients), 23 patients received active treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Fifty-eight patients (58%) presented with spontaneous tumor regression (decrease > 0% compared with the initial size) during the first 3 months (n = 35, 35%) or after an initial progression (n = 23, 23%), of whom 26 (26%) had partial responses (PRs).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Italian prospective multicenter observational study at any site
“This is an Italian prospective, multicenter, observational study (NCT02547831) including patients ≥16 years with primary sporadic DF at any site.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At 32.3-month median follow-up, 42 of 108 (39%) showed RECIST progression. Spontaneous regression was initially observed in 27 of 108 (25%), while it followed dimensional progression in another 33 of 108 (31%). PFS at 36 months was 54.5% [95% confidence interval (CI), 44.9%-66.1%]. Thirty-five of 108 (32%) patients received active treatment, 18 of 108 (17%) after RECIST progression and 17 of 108 (15%) after symptomatic progression. TFS at 36 months was 65.9% (95% CI, 57.3%-75.9%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
GRAFITI prospective cohort study of non-intraabdominal tumors
“In this multicenter prospective cohort study (NTR4714), adult patients with non-intraabdominal DTF were followed during an initial AS approach for 3 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 105 patients started with AS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At 3 years, cumulative incidence of the start of active treatment was 30% (95% confidence interval [CI] 21–39) and PFS was 58% (95% CI 49–69). Median time to start active treatment and PFS were not reached at a median follow-up of 33.7 months. During AS, 32% of patients had stable disease, 28% regressed, and 40% demonstrated initial progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Larger tumor size (≥5 cm; hazard ratio = 2.38 [95% CI 1.15–4.90]) and S45F mutation (hazard ratio = 6.24 [95% CI 1.92–20.30]) were associated with the start of active treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The follow-up protocol of the GRAFITI trial consisted of follow-up visits and imaging examinations (Ultrasound [US] and MRI) at baseline, 3,6,9,12,18,24, and 36 months (window ±3 months).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Single sarcoma reference center cohort at all anatomic locations
“Patients with a primary desmoid tumor at any anatomic location diagnosed between 1998 and 2016 were identified in a prospectively maintained database from a single sarcoma reference center in the United Kingdom.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The study identified 168 patients with a primary desmoid tumor initially managed with active surveillance.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of all the patients, 36% experienced radiologic progressive disease, 36% had stable disease, and 27% regressed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Eventually, 46% of the patients proceeded to treatment. The median time to start of treatment after initial surveillance was 31 months, whereas the median follow-up time for the patients not receiving any treatment was 40.5 months. The indications for initiation of treatment were pain (32%), progression (31%), or both (13%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Use of active surveillance before treatment among survey participants
Surgery
Surgery as second-line treatment for abdominal wall tumors
Resection margins
Surgery compared with observation
Surgery after failure of the surveillance approach
“Multiple retrospective single institution case series have reported local control rates after complete surgical resection to be ∼80% at 5 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When the surveillance approach fails, surgery is still a valid option (IV, A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
NCCN and Desmoid Tumor Working Group positions on first-line surgery
“However, while surgery has historically represented the primary treatment modality for patients with DT, the NCCN Guidelines® and DTWG guidelines no longer support surgery as the first-line option in most situations, given high postsurgical recurrence rates” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, consensus guidance also positions surgery as a primary treatment consideration for patients experiencing complications from sporadic mesenteric DT or for those with non-mesenteric DT that progress despite active surveillance or medical treatment” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Indications for surgery and expected recurrence after resection
Surgical morbidity, postsurgical recurrence, and the criterion of tumors not amenable to surgery or radiotherapy
Prospective cohort of 771 cases: surgery compared with wait-and-see
“We conducted a prospective study of 771 confirmed cases of DTF.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, the 2-year EFS was 56%; this value did not differ between patients undergoing an operation and those managed by the wait-and-see approach (53% versus 58%, p = 0.415).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients with favourable locations, the 2-year EFS was similar in patients treated by both surgery (70%) and the wait-and-see approach (63%; p = 0.413). Among patients with unfavourable locations, the 2-year EFS was significantly enhanced in patients initially managed with the wait-and-see approach (52%) compared with those who underwent initial surgery (25%; p = 0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Recurrence after complete gross resection in a single-institution database
“Patients undergoing resection during 1982-2011 for primary or locally recurrent desmoids were identified from a single-institution prospective database.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Desmoids were treated surgically in 495 patients (median follow-up 60 months). Of 439 patients undergoing complete gross resection, 100 (23%) had recurrence. Five-year local recurrence–free survival (LRFS) was 69%. Eight patients died of disease, all after R2 resection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In multivariate analysis, factors associated with recurrence were extremity location, young age, and large tumor size, but not margin. Abdominal wall tumors had the best outcome (5-year LRFS 91%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Resection margins and local recurrence across sixteen reports
“Sixteen reports were included, consisting of a total of 1295 patients with DF. In patients treated by surgical resection alone, the risk of local recurrence was almost twofold higher for those with microscopically positive resection margins (risk ratio (RR) 1·78, 95 per cent c.i. 1·40 to 2·26).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Recurrence and amputation after surgery reported by participants
“Continued tumor regrowth or recurrence following any DT treatment was reported for 46% (92/202) of participants, with a higher rate post-surgery (63%, 103/163), regardless of tumor location (Fig. 4). Amputation was reported for 7% (12/163) of participants who underwent surgery, with most (83%, 10/12) experiencing tumor regrowth or recurrence post-amputation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Literature review of recurrence and functional deficits after surgery
“We conducted a literature review to assess the burden of surgery in patients with DT, focusing on recurrence rates and functional deficits resulting from surgeries.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Although surgery is a potential treatment option, complete excision with negative margins is not often possible, the postsurgery recurrence rate is high, and surgery can result in disfigurement and/or loss of function.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Tumors in the extremities have the highest risk of recurrence (30%-90%). Lower rates of recurrences have been reported when radiotherapy was used after surgery (14%-38%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Radiotherapy
Moderate-dose definitive radiotherapy when surgery is not an option
Radiotherapy combined with or compared with surgery
Dose of 56 Gy in 28 fractions and post-operative radiotherapy
“Radiotherapy to a dose of 56 Gy in 28 once-daily fractions of 2 Gy has been shown to provide adequate local control in the majority of progressive patients (III, A)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Post-operative radiation has not demonstrated a conclusive benefit after first surgery regardless of resection margins.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Radiotherapy dose, local control, and late effects
EORTC 62991-22998 multicenter prospective phase II trial: local control and response
“To determine the activity of radiotherapy in patients with inoperable desmoid-type fibromatosis (DF) a multicenter prospective phase II trial was carried out.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“(EORTC 62991-22998)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with inoperable progressive disease of primary, recurrent or incompletely resected lesions received a dose of 56 Gy in 28 fractions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Forty-four patients (27 F/17 M) were enrolled from 2001 to 2008. Median age was 39.5 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median follow-up was 4.8 years. The 3-year local control rate was 81.5% (90% one-sided confidence interval 74% to 100%). Best overall response during the first 3 years was complete response (CR) 6 (13.6%), partial response (PR) 16 (36.4%), stable disease 18 (40.9%), progressive disease 3 (6.8%) and nonassessable 1 (2.3%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Response after radiation therapy is slow with continuing regression seen even after 3 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
EORTC 62991-22998 multicenter prospective phase II trial: acute and late toxicity
Review of six studies of definitive radiotherapy for unresectable tumors: local control and late complications
“Among 218 identified studies, only 6 were finally included in this review. Local control was achieved in 253 of 317 patients with unresectable or unresected tumors who underwent definitive radiation therapy (the crude rate of local control was 79.8%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Frequent late complications of radiation therapy included fibrosis/contracture/joint stiffness, skin disorders, lymphedema and pain. Six patients developed secondary malignancies in the radiation field.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Adjuvant radiotherapy after resection with negative or positive margins
“Adjuvant radiotherapy after surgery with negative margins had no detectable benefit on recurrence. In contrast, after incomplete surgical resection, adjuvant radiotherapy improved recurrence rates both in patients with primary tumours (RR 1·54, 1·05 to 2·27) and in those with recurrent DF (RR 1·60, 1·12 to 2·28).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Adjuvant radiation in a surgical series
“In our series, there was no improvement in outcomes in patients who had received radiation therapy during the course of their treatment (5-year LRFS 68% vs 72% without radiation; Figure 3A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“LRFS among patients with extremity tumors was 71% with radiation vs. 56% without (p=0.029).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Criterion of tumors not amenable to surgery or radiotherapy
Cryoablation and other local ablative therapies
Local ablative treatments as an alternative to medical therapies
Consensus update of 2023: positioning of local ablative therapies
“The 2023 update of the global evidence-based consensus guideline focused on the positioning of local therapies alongside surgery and radiotherapy in the treatment algorithm as well as the positioning of the newest class of medical agents, such as γ-secretase inhibitors.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The 2023 consensus guideline is informed by a number of new aspects, including data for local ablative therapies such as cryotherapy; other indications for surgery;” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cryoablation for small and moderately sized extra-abdominal tumors
“Cryoablation has been reported in case series to be an effective alternative treatment of small and moderately sized extra-abdominal DF. It is of limited use in patients with larger tumors that can only be partially treated due to the involvement of vital structures.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of note, both approaches are not available in every center and do require particular expertise.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Isolated limb perfusion for progressive locally advanced extremity tumors
“In patients with progressive, locally advanced extremity DF, where resection would result in important functional sacrifice, isolated limb perfusion (ILP) with tumor necrosis factor alpha and melphalan seems to be a very effective treatment option” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“With a median follow-up of 7 years, 90% of 25 patients had disease control; of these, 40% developed disease progression after a median of 2 years” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This modality can be followed by substantial side effects, although the use of low dose TNF (1 mg) and moderate temperature (never above 39 °C) have made this procedure safer than in the past.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cryotherapy in selected patients
CRYODESMO-01 phase II study: design and non-progression rate at 12 months
“CRYODESMO-01 (ClinicalTrials.gov Identifier: NCT02476305) is a prospective, open-label, non-randomised, non-comparative, multicenter study assessing cryoablation in non-abdominopelvic progressing DT.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The primary end-point was the non-progression rate at 12 months; secondary end-points included safety, quality of life (QoL), assessment of pain and functional status.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“50 pts were enrolled (78% female) from four French centres and all were treated.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The median tumour largest diameter was 89 mm. The rate of non-progressing disease at +12 months was 86% [confidence level (CI) 95% 73-94%]. Median PFS was not reached at a median follow-up of 31 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
CRYODESMO-01 phase II study: toxicity, pain, and function
Matched comparison of cryoablation and surgery
“Twenty-two cryoablation patients were matched with 33 surgical patients (n = 55). Median follow-up after cryoablation was 16.3 months versus 14.9 months after surgery. Two-year local recurrence-free survival (LRFS) was 59% after cryoablation and 71% after surgery, and median LRFS was 26.6 months after cryoablation but was not reached after surgery.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was no significant difference in LRFS or disease control between matched cryoablation and surgical patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Retrospective study of local recurrence after cryoablation
“Eighty-four patients treated for nonabdominopelvic desmoid tumors by cryoablation from July 2012 to July 2020 were included in a retrospective study.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Local relapse was found in 19 (22.62%) of 84 patients. The 12-, 24-, and 36-month progression-free survival rates were 89% (95% confidence interval [CI], 79-94), 74% (95% CI, 60-83), and 68% (95% CI, 53-79), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Systematic review of cryoablation: response, local progression-free survival, and complications
“Five studies were included in the systematic review accounting for 146 patients. Only 18.5% patients received cryoablation as a first-line treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Major complications were noted for 13.3-30% patients and following 2.4-6.7% interventional sessions. The rates of complete tumour response ranged between 0 and 43.3%. 1- and 3-year local progression-free survival rates were 85.1-85.8%, and 77.3-82.9%, respectively. Complete pain relief was reported in 40-66.7% symptomatic patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cryoablation in pediatric and young adult patients
“Twenty-one patients (age 2-22 years; median 14 years), with 21 desmoid tumors, underwent a total of 34 percutaneous cryoablation procedures between August 2013 and August 2023.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“According to modified response evaluation criteria in solid tumors (mRECIST), 71%( 15/21) had partial response (PR), 19% (4/21) had complete response (CR), and 10% (2/21) had stable disease. Four (12%) treatments were associated with minor complications, which self-resolved.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pooled symptom relief and local control across 23 studies of cryoablation, high-intensity focused ultrasound, and microwave ablation
“After literature selection, 694 DF tumors were identified in 23 studies. In terms of modality, 13 studies used cryoablation, 9 studies used high-intensity focused ultrasound (HIFU), and 1 study used microwave ablation (MWA).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The pooled symptom relief rate was 90% [95% confidence interval (CI): 80–97%], with that for HIFU being 100% (95% CI: 85–100%), that for cryoablation being 87% (95% CI: 74–97%), and that MWA being 89% (95% CI).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the subgroup analysis, the rate of local control of MWA was 78% (14), that of HIFU was 99% (95% CI: 99–100%), and that of cryoablation was 80% (95% CI: 68–90%), with these differences being statistically significant” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Major complications across 694 lesions treated with cryoablation, high-intensity focused ultrasound, or microwave ablation
“Of the 694 lesions, 40 were associated with major complications, among which severe nerve injury was the most common (26.3%) (Figure 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The major complication rates for MWA, HIFU, and cryoablation were 11% (14), 2% (95% CI: 0–6%), and 4% (95% CI: 1–8%), respectively. However, the difference was not statistically significant” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Review of high-intensity focused ultrasound in 15 studies of desmoid tumors
“We review the evidence for high-intensity focused ultrasound (HIFU) in the treatment of soft tissue sarcoma (STS) and desmoid tumour (DT).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We identified 12 studies pertaining to STS (n=178) and 15 studies pertaining to DT (n=417). These were prospective phase I/II open-label trials and retrospective case series or reports. The commonest adverse effects were skin burns, transient pain, and fever. Less common adverse effects of nerve injury and bowel perforation were depended on anatomic relations of the tumour.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There was a high degree of variability in the reporting of outcomes making quantitative analysis challenging.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Arterial doxorubicin eluting embolization
“We investigated arterial doxorubicin eluting embolization (DEE), an approach characterized by high drug concentrations in the tumor alongside limited systemic drug exposure.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study included 24 patients (median age, 24; interquartile range, 16–34 years). Data were collected prospectively for 9 patients and retrospectively for 15 patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of 23 patients, 9 (39%), 12 (52%), and 2 (9%) had a partial response, stable disease, and progressive disease, respectively. DEE was safe and well tolerated, with one reported grade 3–4 adverse event (cord injury).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Gamma secretase inhibitors
Nirogacestat: FDA-approved indication and mechanism
Nirogacestat: recommended dosage and dose modifications
Nirogacestat warnings: diarrhea
Nirogacestat warnings: ovarian toxicity
Nirogacestat warnings: hepatotoxicity
Nirogacestat warnings: non-melanoma skin cancers
Nirogacestat warnings: electrolyte abnormalities
Nirogacestat warnings: hypersensitivity reactions, added August 2026
Nirogacestat warnings: embryo-fetal toxicity
Nirogacestat: drug interactions
DeFi phase 3 trial: design
“We conducted a phase 3, international, double-blind, randomized, placebo-controlled trial of nirogacestat in adults with progressing desmoid tumors according to the Response Evaluation Criteria in Solid Tumors, version 1.1. Patients were assigned in a 1:1 ratio to receive the oral γ-secretase inhibitor nirogacestat (150 mg) or placebo twice daily. The primary end point was progression-free survival.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“From May 2019 through August 2020, a total of 70 patients were assigned to receive nirogacestat and 72 to receive placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
DeFi phase 3 trial: efficacy
“The risk of disease progression or death was 71% lower in the nirogacestat group than in the placebo group (hazard ratio, 0.29; 95% confidence interval [CI], 0.15 to 0.55; P<0.001)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The likelihood of being event-free at 1 year was 85% (95% CI, 73 to 92) with nirogacestat and 53% (95% CI, 40 to 64) with placebo. The likelihood of being event-free at 2 years was 76% (95% CI, 61 to 87) with nirogacestat and 44% (95% CI, 32 to 56) with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The percentage of patients with a confirmed objective response was 41% in the nirogacestat group and 8% in the placebo group (P<0.001). Complete responses were observed in 7% of the patients in the nirogacestat group and no patients in the placebo group” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Significant between-group differences in secondary patient-reported outcomes, including pain, symptom burden, physical or role functioning, and health-related quality of life, were observed (P≤0.01).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
DeFi phase 3 trial: safety
“Dose reductions due to adverse events were more frequently reported among patients receiving nirogacestat (42%) than among those receiving placebo (0%) and were attributed primarily to diarrhea, stomatitis, maculopapular rash, hypophosphatemia, hidradenitis, ovarian failure, and folliculitis. Adverse events led to discontinuation of the trial regimen in 14 patients (20%) in the nirogacestat group and 1 patient (1%) in the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ovarian dysfunction (defined by the MedDRA preferred terms of amenorrhea, premature menopause, menopause, and ovarian failure) occurred in 27 of 36 women of childbearing potential (75%) receiving nirogacestat and in 0 of 37 receiving placebo. The median time to first onset of ovarian dysfunction was 8.9 weeks, and the median duration across ovarian dysfunction events was 19.1 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although long-term treatment with nirogacestat was shown to be feasible (median treatment duration, 20.6 months), the appropriate treatment duration is unknown.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
DeFi long-term follow-up through December 2024
“Here, long-term nirogacestat efficacy and safety were evaluated in patients randomly assigned to nirogacestat and followed through the final data cutoff date of December 19, 2024.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median (range) duration of exposure was 33.6 (0.3-61.8) months. Median PFS was not reached. The ORR with up to 4 years of nirogacestat treatment was 45.7% (32 of 70), with three additional partial and three additional complete responses since the primary analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 70 patients randomly assigned to nirogacestat in the DB phase, 39 continued in the OLE” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 33 and 15 patients received nirogacestat for at least 3 and 4 years, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No additional events (progression or death) occurred with additional exposure after year 2” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The ORR was 34.3%, 41.4%, 44.3%, and 45.7% in patients who received nirogacestat for up to 1, 2, 3, and 4 years, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Since the primary analysis, four patients discontinued nirogacestat because of TEAEs between years 2 and 4.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Optimal duration of treatment and the presence and frequency of additional tumor responses after treatment discontinuation are not well defined.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
DeFi ovarian toxicity: onset and resolution in females of reproductive potential
“This analysis further describes the incidence, presentation, and resolution of OT.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“OT was identified in 75% (27 of 36) receiving nirogacestat and 0% (0 of 37) receiving placebo. As of October 24, 2022, investigators reported OT resolution in 78% (21 of 27) of patients, with median OT duration of 19.1 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Off-treatment resolution was reported in all 11 patients (100%) who stopped nirogacestat treatment” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Resolution was reported in 10 of 14 (71%) while on nirogacestat” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Most FORP treated with nirogacestat experienced OT, with the majority resolving, including all who stopped treatment, suggesting that OT is transient.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Duration of nirogacestat treatment: DeFi investigators' reply on long-term use
“We do not endorse long-term uninterrupted treatment with nirogacestat as the standard of care. Still, as both groups of authors have acknowledged, the optimal treatment duration remains undefined.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, patients in DeFi were censored at the time nirogacestat was discontinued and were followed for no more than 30 days after treatment discontinuation. Therefore, the absence of progression events after year 2 reflects only the cohort of patients who continued treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Real-world nirogacestat use in the French compassionate use program (DeNi study)
“The DeNi study reports outcomes of patients treated with nirogacestat through the French compassionate use program. DeNi is a retrospective, real-world study.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Between February and June 2024, 55 patients with desmoid tumors were included (37 women).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Partial response and stable disease were observed in 33 (60%) and 17 patients (31%), respectively. The 1-year PFS rate was 76.2%, and 77.0% of patients remained without treatment change at 1 year, including patients with dose reductions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 49 patients with baseline pain, 38 (78%) experienced pain improvement under nirogacestat; 35 (71%) reduced or discontinued analgesics.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The most frequent side effects (all grades) were diarrhea (53%), fatigue (47%), and rash (29%). Thirteen patients (24%) required dose reduction: 11 for digestive adverse events (85%), 1 for mucositis, and 1 for fatigue with hypertension.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
NCCN guideline status as restated in a payer policy and in a DeFi publication
“Nirogacestat, an oral, targeted gamma secretase inhibitor, is the only US Food and Drug Administration–and European Commission–approved therapy for adults with progressing DT who require systemic treatment and is recommended as a preferred therapy by the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
European marketing authorisation of nirogacestat
“Approval from the European Commission was obtained in August 2025 and from the UK Medicines and Healthcare Products Regulatory Agency in January 2026.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, as of this writing, nirogacestat is still not widely available outside of the United States.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
NICE technology appraisal TA1199 recommendation, October 2026
Tyrosine kinase inhibitors
NCCN placement of sorafenib, imatinib, and pazopanib as quoted in a payer policy
Guideline updates naming sorafenib a category 1 preferred regimen
“After this analysis ended in August 2023 and the United States Food and Drug Administration (FDA) approval of nirogacestat, the NCCN Guidelines and DTWG guidelines were updated to include sorafenib and nirogacestat as Category 1, Preferred systemic regimens [14, 16, 18].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Desmoid Tumor Working Group assessment of tyrosine kinase inhibitors
Sorafenib phase 3 trial: design and efficacy
“In this double-blind, phase 3 trial, we randomly assigned 87 patients with progressive, symptomatic, or recurrent desmoid tumors to receive either sorafenib (400-mg tablet once daily) or matching placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“With a median follow-up of 27.2 months, the 2-year progression-free survival rate was 81% (95% confidence interval [CI], 69 to 96) in the sorafenib group and 36% (95% CI, 22 to 57) in the placebo group (hazard ratio for progression or death, 0.13; 95% CI, 0.05 to 0.31; P<0.001). Before crossover, the objective response rate was 33% (95% CI, 20 to 48) in the sorafenib group and 20% (95% CI, 8 to 38) in the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median time to an objective response among patients who had a response was 9.6 months (interquartile range, 6.6 to 16.7) in the sorafenib group and 13.3 months (interquartile range, 11.2 to 31.1) in the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On the basis of the predictable toxic-effects profile and substantial progression-free survival advantage conferred by sorafenib, the drug has antitumor activity as first-line therapy or as subsequent therapy for desmoid tumors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sorafenib phase 3 trial: adverse events, dose modification, and discontinuation
“Among patients who received sorafenib, the most frequently reported adverse events were grade 1 or 2 events of rash (73%), fatigue (67%), hypertension (55%), and diarrhea (51%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Dose interruptions occurred in 65% of the patients in the sorafenib group (32 of 49) and 34% of the patients in the placebo group (12 of 35), and dose reductions due to toxic effects occurred in 31% (15 of 49) and 11% (4 of 35), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events led to a significantly higher rate of discontinuation of the trial regimen in the sorafenib group than in the placebo group (20% vs. no patients).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Grade 3 adverse events that were attributed to the trial regimen by the investigators occurred in 29% of patients in the sorafenib group and 14% of patients in the placebo group. Grade 4 events that were associated with sorafenib included thrombocytopenia (2%) and anemia (2%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pazopanib in the DESMOPAZ randomized phase 2 trial
“DESMOPAZ was a non-comparative, randomised, open-label, phase 2 trial conducted at 12 centres from the French Sarcoma Group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Participants were randomly assigned (2:1) to oral pazopanib 800 mg per day for up to 1 year or to an intravenous regimen combining vinblastine (5 mg/m2 per dose) and methotrexate (30 mg/m2 per dose), administered weekly for 6 months and then every other week for 6 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the first 43 patients assessable for the primary endpoint in the pazopanib group, the proportion of patients who had not progressed at 6 months was 83·7% (95% CI 69·3-93·2).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The most common grade 3 or 4 adverse events in the pazopanib group were hypertension (n=10, 21%) and diarrhoea (n=7, 15%)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“11 patients (23%) had at least one serious adverse event related to study treatment in the pazopanib group” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Imatinib in the German Interdisciplinary Sarcoma Group phase 2 trial
“We initiated a phase II trial within the German Interdisciplinary Sarcoma Group (GISG) evaluating imatinib to induce progression arrest” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Thirty-eight patients (median age 44 years [range: 19-80]; 68% female; 90% Eastern Cooperative Oncology Group (ECOG) performance status 0) were treated with a daily dose of 800 mg imatinib planned over 2 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The final analysis for the primary end-point in the evaluable patients of the full analysis set revealed a PAR6mo of 65%. Subsequent progression arrest rates at 9, 12, 15, 18, 21 and 24 months were 65%, 59%, 53%, 53%, 50% and 45%, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Best reported response was seven partial responses at 21 months revealing an overall response rate of 19%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In general imatinib adverse events were mild to moderate.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Imatinib in a two-stage phase 2 study
“Forty patients with unresectable and progressive symptomatic AF/DT were treated with imatinib (400 mg/day for 1 year) in a Simon's optimal two-stage phase II study” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The non-progression rates at 3, 6 and 12 months were, respectively, 91%, 80% and 67%. The 2-year progression-free and overall survival rates were 55% and 95%, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Real-world sorafenib and pazopanib in an 11-institution retrospective cohort
“Patients diagnosed with DTs and treated with sorafenib or pazopanib between 2011 and 2022 at 11 institutions were reviewed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“142 patients with DT treated with sorafenib (n = 126, 88.7 %) or pazopanib (n = 16, 11.3 %) were analyzed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The overall response rate and the disease control rate were 26.0 % and 95.1 %, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The 1-year and 2-year progression-free survival rates were 82 % and 80 %. Dose reductions were necessary in 34 (23.9 %) patients. Grade 3 or higher adverse events were reported in 36 (25.4 %) patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment discontinuation (n = 85, 59.9 %) was mainly for toxicity (n = 35, 45.9 %) or radiological or clinical progression (n = 30, 35.3 %).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Sorafenib discontinuation after response in the SORASTOP phase 2 study
“The SORASTOP study reports long-term outcomes following planned sorafenib discontinuation in responding patients with extremity desmoid-type fibromatosis (DTF).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In this prospective, single-arm phase 2 Simon's two-stage trial, adults with non-progressive, extremity DTF, ESAS pain < 2, after ≥ 12 months of sorafenib were enrolled.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“PFS at 12, 24 and 36 months were 90.8 %, 74.5 % and 74.5 % respectively; with median follow-up of 37 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Tyrosine kinase inhibitor use reported by study participants
“Most participants (76%, 281/369) received systemic therapy (any line), including nonsteroidal anti-inflammatory drugs (NSAIDs; 40%, 112/281), tyrosine kinase inhibitors (32%, 91/281), chemotherapy (31%, 87/281), and hormone antagonists (17%, 47/281; Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Funding status of tyrosine kinase inhibitors in England
Chemotherapy
NCCN placement of methotrexate-based and doxorubicin-based regimens as quoted in a payer policy
Guideline updates naming chemotherapy regimens category 2A
“Additionally, the NCCN Guidelines were updated to include methotrexate with vinorelbine; methotrexate with vinblastine, imatinib, and liposomal doxorubicin; doxorubicin with or without dacarbazine; and pazopanib as Category 2A regimens [14].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Desmoid Tumor Working Group assessment of chemotherapy
Desmoid Tumor Working Group approach to sequencing systemic therapies
Methotrexate plus vinblastine in the DESMOPAZ randomized phase 2 trial
“The proportion of patients treated with methotrexate-vinblastine who had not progressed at 6 months was 45·0% (95% CI 23·1-68·5).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“in the methotrexate-vinblastine group were neutropenia (n=10, 45%) and liver transaminitis (n=4, 18%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“six patients (27%) in the methotrexate-vinblastine group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Methotrexate plus vinblastine or vinorelbine in a 25-year institutional series
“Herein, we report on our institutional experience with low-dose methotrexate (MTX) + vinca alkaloids in this disease over the last 25 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We identified 75 patients treated with MTX + vinblastine (40%), MTX + vinorelbine (57%), and vinorelbine alone (3%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Eight patients interrupted chemotherapy because of toxicity. According to RECIST (Response Evaluation Criteria in Solid Tumors) complete response, partial response, stable disease, and progressive disease were observed in 1%, 47%, 51%, and 1% of patients, respectively. Symptomatic relief was obtained in 80% of symptomatic cases. The median progression-free survival (PFS) was 75 months; it was 136 months in responding patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Methotrexate plus vinorelbine in a retrospective institutional series
“Patients with biopsy‐proven DF, treated with MTX/VNL from 1997 to 2015 were reviewed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among 48 patients treated for a median 19 months MTX/VNL, only nine (19%) had previous surgery.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median progression‐free survival (PFS) was 120 months, (95%CI 84‐155 months).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most common grade 1/2 toxicities included nausea (n = 12, 25%) and fatigue (n = 9,19%) with no grade 3/4 toxicities.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Methotrexate plus vinblastine in children in a Pediatric Oncology Group phase 2 trial
“A phase II study was conducted within the Pediatric Oncology Group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients were treated using Vbl (5 mg/m2/dose) and Mtx (30 mg/m2/dose), both administered by intravenous injection weekly for 26 weeks and every other week for an additional 26 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A measurable response was documented in eight patients (31%), and 10 patients had stable disease documented as the best response to treatment. Eighteen patients had disease progression at a median time of 9.1 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Neutropenia was the most common toxicity (n = 22) and the most common grade 4 toxicity (n = 5).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Biweekly methotrexate plus vinblastine in a single-institution prospective cohort
“The aim of this study was to determine the clinical outcomes of a biweekly regimen in a cohort prospectively treated in our single institution.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Since 2010, we have prospectively treated refractory DF patients with biweekly MTX (30 mg/m2) + VBL (6 mg/m2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nineteen (51%) patients showed partial response (PR). Clinical benefit rate was 95%. PFS at 5 y was 80.8%. In PR cases, median time to response was 10 mo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Only 3 AEs of grade 3/4 were observed. Tumor regrowth after MTX + VBL discontinuation was observed in 5 (20%) of 25 patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Methotrexate plus vinblastine after meloxicam failure in an institutional cohort
“Since March 2003, patients pathologically diagnosed with extraperitoneal desmoid tumors have been prospectively treated with meloxicam, a COX-2 inhibitor, at our institution.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with inoperable tumors who were resistant to meloxicam treatment underwent MTX and VBL therapy every other week.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“MTX + VBL therapy was administered in 15 patients. Six patients showed a partial response. Only one patient presented disease progression.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Systematic review of low-dose methotrexate plus vinblastine
“There were three prospective case series but no randomized controlled trials among the nine studies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“According to Response Evaluation Criteria in Solid Tumors criteria, the mean response rate (complete remission or partial response) was 36% (11-57%). Including stable disease, namely, clinical benefit was consistently as high as 85% (69-100%). Mean adverse event rate of G3 or G4 according to CTCAE was 31%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“However, the overall evidence was weak, and this chemotherapy is not covered by insurance in Japan; we only weakly recommend low-dose chemotherapy with methotrexate and vinblastine in patients with extra-abdominal desmoid-type fibromatosis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Doxorubicin-based chemotherapy in a French Sarcoma Group series
“Records of patients with DT who were treated with CT in centers from the French Sarcoma Group were reviewed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Sixty-two patients entered the study.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Thirteen patients (21%) received an anthracycline-containing regimen. The most frequent nonanthracycline regimen was the methotrexate-vinblastine combination (n=27).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The response rate was higher with anthracycline-containing regimens: 54% versus 12%, P=0.0011. Median progression-free survival (PFS) was 40.8 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Systematic review of doxorubicin-based and liposomal doxorubicin chemotherapy
“There were no randomized controlled trials. According to response evaluation criteria in solid tumors criteria, the response rates of doxorubicin-based regimens and liposomal doxorubicin were 44% (28.6-54) and 33.3% (0-75) on average, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The rates of G3 or G4 complications according to common terminology criteria for adverse events were 28% and 13% with doxorubicin-based and liposomal doxorubicin chemotherapy, respectively, including neutropenia or cardiac dysfunction.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We weakly recommend doxorubicin-based chemotherapy for patients with extra-abdominal desmoid-type fibromatosis in cases resistant to other treatments.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Anthracycline-containing regimens compared with sorafenib in a retrospective multi-institutional analysis
“The authors conducted a multi-institutional retrospective analysis of desmoid tumor patients treated with either sorafenib or an anthracycline-containing regimen over 1 year.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“From 2005 to 2022, 80 patients received sorafenib and 51 received an anthracycline-containing regimen with similar baseline characteristics. The 1-year ORR was 37% for anthracycline and 13% for sorafenib (p = .016).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“One-year PFS was 73% (95% CI, 60-86) for anthracycline and 59% (95% CI, 47-71) for sorafenib (p = .3).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Grade 3 events were higher in the anthracycline group, 27% versus 14% (p < .05).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pegylated liposomal doxorubicin in a placebo-controlled phase 3 trial
“In this investigator-initiated, double-blind, phase III trial, we randomly assigned (in a 2:1 ratio) patients with advanced or refractory DTs to receive either PLD (50 mg/m2 intravenously) or placebo every 4 weeks for six cycles.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“From November 2020 to March 2023, a total of 73 patients were assigned to receive PLD (49 patients) or placebo (24 patients). With a median follow-up of 16.1 months, PLD had a significantly longer PFS over placebo (not reached vs. 4.3 months), with an HR of 0.05 (95% confidence interval, 0.01–0.17; P < 0.001). The 2-year PFS rates were 90.4% with the PLD group and 19.6% with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The confirmed objective response was observed in 19 (40.4%) patients in the PLD group and in one (4.3%) in the placebo group (P = 0.002).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Seven (14.9%) patients experienced grade 3 or 4 AEs in the PLD group, including neutrophil count decreased (10.6%), mucositis oral (6.4%), white cell decreased (4.3%), and palmar–plantar erythrodysesthesia syndrome (2.1%). No patients reported cardiotoxicity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“First, the interpretation of our results is limited by a single-center design and relatively small sample size, which had the potential to introduce bias, although these aspects are consistent with other phase III trials in this rare disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Lastly, the current follow-up period may not be sufficient to adequately assess the cardiotoxicity associated with low cumulative doses of PLD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Chemotherapy use and sequence in the United Kingdom
Chemotherapy agents reported by study participants
Nonsteroidal anti-inflammatory drugs and hormonal therapy
Desmoid Tumor Working Group position on antihormonal therapies and NSAIDs
Hormone antagonists no longer recommended by the Desmoid Tumor Working Group
“Note that nirogacestat was not approved for use at the time of survey completion [18], and hormone antagonists are no longer recommended by Desmoid Tumor Working Group Consenus Guidelines [13]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The use of NSAIDs and hormone antagonists reported in this study is only recommended for certain circumstances by evidence-based guidelines [14, 16].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
NCCN placement of NSAIDs for pain as quoted in a payer policy
“Sulindac or other nonsteroidal” (opens the source at this quote in a new tab)
“including celecoxib, are recommended for pain under” (opens the source at this quote in a new tab)
“Useful in Certain Circumstances” (opens the source at this quote in a new tab)
“(category 2A).” (opens the source at this quote in a new tab)
European consensus position on antihormonal therapy, 2017, superseded in 2020
“Anti-hormonal agents such as tamoxifen may be used—alone [60] or in combination with NSAIDs [61]—as first medical treatment, mainly because of their limited toxicity, rare adverse events and low costs [62] (III, B). However, response rates have been found to be low and no clear relationship between symptom changes, size or MRI signal changes could be demonstrated [63]. Therefore, a general recommendation for its use cannot be given.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
High-dose tamoxifen plus sulindac in a German institutional series
“Since 1992, 25 patients at Heinrich Heine University (Dusseldorf, Germany) were treated with a combination of tamoxifen and sulindac.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the current study, 17 patients with FAP-associated and 8 patients with sporadic desmoid tumors received 120 mg of tamoxifen and 300 mg of sulindac daily.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of the group of patients who received tamoxifen and sulindac as a primary treatment, all three patients with sporadic desmoid tumors demonstrated cessation of growth, and 10 of the 13 patients with FAP-associated tumors achieved either a PR or CR.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Based on this experience, the authors recommended high-dose tamoxifen and sulindac as the primary treatment for patients with FAP-associated desmoid tumors.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
High-dose selective estrogen receptor modulators plus sulindac in an institutional cohort
“This study included all desmoid patients that were treated and followed at our institution and had completed at least 1 year of treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 134 patients were included. 64 (47.8 %) patients had a confirmed diagnosis of FAP, 69 (51.5 %) patients were sporadic. Overall 114 (85.1 %) patients showed regressive or stable desmoid size.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Response was defined as stable size or regression of desmoid size between two CT or MRI scans.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Tamoxifen plus sulindac in children in a Children's Oncology Group phase 2 study
“We evaluated the safety and efficacy of tamoxifen and sulindac in a prospective phase II study within the Children’s Oncology Group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No life-threatening toxicity was reported. Twelve (40%) of 30 females developed ovarian cysts, which were asymptomatic in 11 cases. Ten patients completed therapy without disease progression or discontinuing treatment. Responses included four partial and one complete (5/59, 8%). The estimated 2-year PFS and survival rates were 36% (95% confidence interval: 0.23–0.48) and 96%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, the combination showed relatively little activity as measured by response and PFS rates.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Toremifene in a retrospective reference-institution series
“We retrospectively reviewed all patients treated with toremifene between 2005 and 2012 at a reference institution.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Forty-four patients were treated with toremifene 180 mg daily, 20 for radiological progression, 16 for pain and 8 for both.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“PFS was 89.6% at 2 years. According to Response Evaluation Criteria in Solid Tumours, partial response, stable disease and disease progression were observed in 25%, 65% and 10% of the patients, respectively. Symptomatic relief was obtained in 75% of patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events G≥2 according to National Cancer Institute Common Toxicity Criteria were recorded in ten patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Toremifene at two dose levels in a prospective phase 2 study
“In order to test the dose efficacy and assess activity and safety of toremifene in DF, we conducted this prospective phase 2 study (NCT02353429).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The 6 and 12 months progression-free survival (PFS) probability was 14.4% (95% CI, 5.1-41.1) and 4.8% (95% CI, 0.7-32.6) for patients receiving 60 mg compared with 72.0% (95% CI, 54.2-96.2) and 52.5% (95% CI, 33.1-83.3) for those receiving 180 mg.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“No toremifene-related serious adverse events were observed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Toremifene at 60 mg daily is ineffective in this patient population. However, clinical benefit was observed at 180 mg in selected cases.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Systematic review of anti-oestrogen therapy
“Data on 168 DTs treated with anti-oestrogen agents, alone or in combination with nonsteroidal anti-inflammatory drugs, were identified with an overall response rate of 51%. There was no difference in response according to the type of DTs or between different anti-oestrogen therapies. Combination with anti-inflammatory drugs did not improve the outcome.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Despite potential inaccuracies in the methodology, the results of the review indicate that anti-oestrogen therapy produces some effect in about one half of patients with DTs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Meloxicam response and CTNNB1 mutation status
“Of the 33 patients with meloxicam treatment, one showed complete remission (CR), 7 partial remission (PR), 12 stable disease (SD), and 13 progressive disease (PD).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“S45F mutation was significantly associated with a poor response (all cases; PD) (p = 0.017), whereas the other mutations had no impact on efficacy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
NSAID and hormone antagonist agents reported by study participants
Limitations of current therapies
Summary: limitations of active surveillance and local therapies
- Active surveillance: in a pooled analysis of 282 participants, 93 (33.0%) received active treatment after initial surveillance, and the 5-year crude cumulative incidence of RECIST progression was 34%. In a United Kingdom cohort of 168 participants, 46% proceeded to treatment, for pain (32%), progression (31%), or both (13%). Guidelines call for a first MRI within 1-2 months and then imaging at 3-6 month intervals, and surveillance may not be appropriate if progression could “be life-threatening or pose a risk for mutilation”.
- Surgery: NCCN and Desmoid Tumor Working Group guidelines “no longer support surgery as the first-line option in most situations” because of high postsurgical recurrence rates. Reported postsurgical recurrence reaches 50% to 88%, and 30%-90% for extremity tumors; after complete gross resection, 23% of patients had recurrence. In unfavorable locations, 2-year event-free survival was 25% after initial surgery and 52% with wait-and-see. Amputation was reported by 7% (12/163) of survey participants who had surgery, and 83% of them reported regrowth or recurrence afterward.
- Radiotherapy: in the EORTC 62991-22998 phase II trial (44 participants), the 3-year local control rate was 81.5% and response was slow. A review of 317 participants treated with definitive radiation reported local control in 79.8%, frequent late fibrosis, contracture, joint stiffness, skin disorders, lymphedema, and pain, and 6 secondary malignancies in the radiation field. The evidence for adjuvant radiotherapy is low, and it carries a risk of radiation-induced sarcoma “in this young patient population”.
- Ablation: in CRYODESMO-01 (50 participants), the 12-month non-progression rate was 86%, and grade 3-4 toxicity occurred in 22%. A systematic review of 146 participants reported major complications in 13.3-30%, and across 694 lesions treated with cryoablation, HIFU, or microwave ablation, severe nerve injury was the most common major complication (26.3%). Cryoablation is of limited use for larger tumors involving vital structures, and ablative approaches are not available in every center and require particular expertise.
Summary: limitations of systemic therapies
- Comparative evidence: the Desmoid Tumor Working Group stated that “due to the lack of comparative studies” no definitive sequence of systemic treatments could be proposed, with randomized data then existing for sorafenib, pazopanib, and methotrexate plus vinblastine. The NCCN guidelines (version 1.2025, as restated in a Cigna policy) list nirogacestat and sorafenib as category 1 and the other listed agents as category 2A.
- Gamma secretase inhibitors: in DeFi, dose reductions due to adverse events occurred in 42% of nirogacestat recipients (0% with placebo) and discontinuation due to adverse events in 20% (1% with placebo); ovarian dysfunction occurred in 27 of 36 women of childbearing potential (75%), with resolution reported in 78% (21 of 27) as of October 24, 2022, including all 11 who stopped treatment. The label carries warnings for diarrhea, ovarian toxicity, hepatotoxicity, non-melanoma skin cancers, electrolyte abnormalities, hypersensitivity reactions (added in August 2026), and embryo-fetal toxicity, and advises avoiding strong or moderate CYP3A inhibitors and inducers and gastric acid reducing agents. The appropriate treatment duration is unknown, and nirogacestat is “still not widely available outside of the United States”.
- Tyrosine kinase inhibitors are used off label and are not commissioned in the NHS in England for desmoid tumours. In the sorafenib phase 3 trial, adverse events led to discontinuation in 20% (no placebo patients), dose reductions due to toxic effects occurred in 31% vs 11%, and grade 1 or 2 rash occurred in 73%. In an 11-institution cohort of 142 participants treated with sorafenib or pazopanib, 59.9% discontinued treatment, mainly for toxicity. Imatinib trials showed response rates of 6–19%, and in DESMOPAZ grade 3 or 4 hypertension occurred in 21% of the pazopanib group.
- Chemotherapy is “not licensed for treating desmoid tumours” (NICE). Response rates are in the range of 35–40% and usually occur several months after the start of therapy. In DESMOPAZ, 45.0% of the methotrexate-vinblastine group had not progressed at 6 months, and neutropenia occurred in 45%. Systematic reviews reported grade 3 or 4 adverse event rates of 31% for low-dose methotrexate plus vinblastine and 28% for doxorubicin-based regimens, and grade 3 events were more frequent with anthracycline regimens than with sorafenib (27% vs 14%). NICE judged the hazard ratio of 0.05 for chemotherapy versus placebo in Xu et al. “implausibly large”, and experts stated that pegylated liposomal doxorubicin is not used for desmoid tumours in the UK.
- Hormonal therapy and NSAIDs: the Desmoid Tumor Working Group found “no evidence to consider antihormonal therapies and NSAIDs”, and hormone antagonists are no longer recommended in its consensus guidelines; NCCN lists sulindac or other NSAIDs for pain as useful in certain circumstances (category 2A). In a Children's Oncology Group phase II study of tamoxifen plus sulindac, responses occurred in 8% (5/59), 2-year PFS was 36%, and 12 of 30 females (40%) developed ovarian cysts. Toremifene 60 mg daily was ineffective (12-month PFS 4.8%), and the S45F mutation was associated with poor response to meloxicam.
Place in treatment, anticipated use, and care setting
Summary
- The NDA under FDA review proposes varegacestat “for the treatment of adults with desmoid tumors”.
- The Desmoid Tumor Working Group considers active surveillance the first step after diagnosis in the majority of patients and proposes active treatment only in case of persistent progression. Treatment choice is guided by anatomical site: surgery remains the first option at progression for abdominal wall tumors, systemic therapy is the first option for intra-abdominal, retroperitoneal, and pelvic tumors, and medical therapy is preferred for extremity, girdle, and chest wall tumors and is first line for head and neck and intrathoracic tumors. The group states that no definitive sequence of systemic treatments can be proposed because comparative studies are lacking.
- The 2023 global consensus update addressed the positioning of gamma secretase inhibitors, with nirogacestat the first approved drug for desmoid tumors. NCCN soft tissue sarcoma guidelines version 1.2025, as quoted in a Cigna coverage policy, list Ogsiveo and sorafenib as category 1 and methotrexate-based, imatinib, pazopanib, and doxorubicin-based regimens as category 2A.
- The approved gamma secretase inhibitor, OGSIVEO (nirogacestat), is indicated for adult patients with progressing desmoid tumors who require systemic treatment, at 150 mg orally twice daily until disease progression or unacceptable toxicity. NICE recommends nirogacestat within its marketing authorisation; in its appraisal, current options in England are off-label chemotherapy, off-label tyrosine kinase inhibitors, and surgery, and nirogacestat is expected to displace chemotherapy and best supportive care.
- RINGSIDE Part B enrolled 156 participants with progressive disease (tumor growth of at least 20% within the past 12 months) who were either treatment-naïve with tumors not amenable to surgery or had refractory or recurrent disease after at least one line of therapy.
- Immunome states that systemic therapy is recommended for about 75% of tumors after progression during initial active surveillance, that gamma secretase inhibitors “may ultimately capture much of the market for desmoid tumor therapy”, and that it aims to “Become Standard of Care treatment of Desmoid Tumors”. It describes varegacestat as oral and once daily, estimates “10-11k Actively Managed Patients (US)”, and anticipates that patients may receive about 1.5 to 2 years of treatment, pause, and return for treatment.
- Immunome plans to commercialize in the United States through a targeted sales force designed to reach specialized treatment centers, and its corporate presentation names about 85 sarcoma centers of excellence.
Proposed indication under FDA review
Active surveillance as the first step and active treatment after persistent progression
“An initial watchful waiting approach is useful to document actual tumor progression. Active therapies need to be individualized on a multidisciplinary basis for patients with clearly progressing disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment choice by anatomical site in the global consensus algorithm
Positioning of gamma secretase inhibitors in the 2023 global consensus update
“The 2023 update of the global evidence-based consensus guideline focused on the positioning of local therapies alongside surgery and radiotherapy in the treatment algorithm as well as the positioning of the newest class of medical agents, such as γ-secretase inhibitors.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The 2023 consensus guideline is informed by a number of new aspects, including data for local ablative therapies such as cryotherapy; other indications for surgery; and the γ-secretase inhibitor nirogacestat, the first representative of the newest class of medical agents and first approved drug for DT.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Sequence of systemic therapies
NCCN preferred systemic regimens for desmoid tumors
Labeled population and dosing of the approved gamma secretase inhibitor
Treatment pathway and displaced treatments in England
RINGSIDE Part B population of treatment-naive and previously treated progressing disease
Oral once-daily administration and anticipated treatment duration
Care setting in sarcoma centers and specialized treatment centers
Heterogeneity of treatment effect
RINGSIDE Part B progression-free survival across subgroups
“Age ≤30 / >30 years” (opens the source at this quote in a new tab)
“Tumor location intra-/extra-abdominal” (opens the source at this quote in a new tab)
“CTNNB1 mutation (S45F+S45P T41A)” (opens the source at this quote in a new tab)
“Baseline tumor size >10 / ≤10 cm” (opens the source at this quote in a new tab)
“Prior systemic DT therapy (yes/no)” (opens the source at this quote in a new tab)
RINGSIDE Part A objective response by subgroup
DeFi progression-free survival across prespecified subgroups
CTNNB1 S45F mutation and recurrence after surgery
“The estimated 5-year recurrence-free survival rate was 23% (95% CI, 10 to 40%) for patients with 45F mutation compared to 57% (95% CI, 43 to 69%), and 65% (95% CI, 38 to 83%) for 41A mutation and nonmutated CTNNB1, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The estimated 3-year and 5-year RFS rates were 0.49 and 0.45, respectively, for patients who had tumors with the S45F mutation; 0.91 and 0.91, respectively, for patients who had wild-type tumors; and 0.70 and 0.66, respectively, for all others” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This series confirmed that primary, completely resected, sporadic DTs with the S45F mutation have a greater tendency for local recurrence.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
CTNNB1 mutation, tumor size, and location during active surveillance
“In multivariable analysis, larger tumor size, mutation type, and tumor locations were associated with lower TFS. The specific mutation (S45F), larger tumor size, and extremity and trunk locations were all associated with a lower probability of spontaneous RECIST regression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Initial tumor size, CTNNB1 mutation, and location should be factored into the initial decision-making process.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tumor location and outcome of surgery compared with a wait-and-see approach
“The 2-year EFS was 66% for favourable locations (abdominal wall, intra-abdominal, breast, digestive viscera and lower limb) and 41% for unfavourable locations. Among patients with favourable locations, the 2-year EFS was similar in patients treated by both surgery (70%) and the wait-and-see approach (63%; p = 0.413). Among patients with unfavourable locations, the 2-year EFS was significantly enhanced in patients initially managed with the wait-and-see approach (52%) compared with those who underwent initial surgery (25%; p = 0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Age, tumor site, and tumor size and recurrence after resection
“In multivariate analysis, factors associated with recurrence were extremity location, young age, and large tumor size, but not margin. Abdominal wall tumors had the best outcome (5-year LRFS 91%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Systemic therapies may be appropriate for young patients with large, extremity desmoids, but surgery alone is curative for most abdominal wall lesions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Familial adenomatous polyposis-associated and intra-abdominal desmoid tumors
Age and reproductive potential in the selection of a gamma secretase inhibitor
Care management intervention strategies
Management in designated referral centers with a multidisciplinary tumor board
“Management of DT is complex and should be carried out exclusively in designated DT referral centers equipped with a multidisciplinary tumor board. Selection of the appropriate strategy should consider DT-related symptoms, associated risks, tumor location, disease morbidities, available treatment options, and preferences of individual patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A multidisciplinary discussion in soft tissue tumor boards is necessary to propose a personalized management; furthermore, a discussion with the patient is also necessary for tailoring this proposal to its objectives given the natural course of the disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Second opinion by an expert pathologist as well as clinical management by an expert team is highly recommended” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Soft Tissue Sarcomas and the Desmoid Tumor Working Group (DTWG) Global Consensus Paper Guidelines state that diagnosis and treatment be informed and supported by a multidisciplinary team” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Supportive care, pregnancy, and family planning
“Individualized counseling is essential for managing risks of progression and recurrence, supporting informed fertility decisions. Referral to specialized centers is recommended to optimize DF management during family planning and pregnancy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Monitoring requirements in the approved gamma secretase inhibitor label
Diarrhea management with nirogacestat in oncology practices
Ovarian toxicity monitoring and fertility counseling
“Off-treatment resolution was reported in all 11 patients (100%) who stopped nirogacestat treatment; of these, all nine with available menstruation information experienced return of menstruation and eight had FSH WNL at last reported assessment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Visit and laboratory frequency during nirogacestat treatment
Dose modification to maintain gamma secretase inhibitor treatment
“Thirteen patients (24%) required dose reduction: 11 for digestive adverse events (85%), 1 for mucositis, and 1 for fatigue with hypertension.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Onset of adverse events with varegacestat in RINGSIDE Part B
| Adverse event (varegacestat, N=79) | All grades, n (%) | Median time to onset (days) |
|---|---|---|
| Diarrhea | “65 (82.3)” | “14.0” |
| Nausea | “28 (35.4)” | “8.0” |
| Rash | “56 (70.9)” | “24.0” |
| Fatigue | “46 (58.2)” | “27.5” |
| Hypophosphatemia | “27 (34.2)” | “29.0” |
| Ovarian toxicity | “20 (25.3)” | “56.5” |
Commercial payer prior authorization criteria for nirogacestat
State Medicaid prior authorization criteria for nirogacestat and new antineoplastics
“LENGTH OF AUTHORIZATION: Varies; Maximum of one year” (opens the source at this quote in a new tab)
“60 per 30 days (100mg and 150mg)” (opens the source at this quote in a new tab)
Other product development or post-marketing obligations required by the FDA
Not applicable.
Ongoing post-approval monitoring
Not applicable.
Expected outcomes of therapy
Summary
- Treatment of progressing desmoid tumors aims to control tumor growth and relieve symptoms. NICE describes it as “non-curative and aims to control tumour growth and alleviate symptoms”, the 2023 consensus update calls for selecting each patient's management strategy to optimize tumor control and enhance quality of life, and Immunome states that treatment goals extend beyond tumor shrinkage to include symptom relief and improved physical function.
- Tumor control with varegacestat in RINGSIDE Part B (data cutoff October 7, 2025): PFS of 94% at 1 year and 89% at 2 years with varegacestat, compared with 66% and 57% with placebo; a hazard ratio of 0.16 (95% CI 0.071, 0.375) and a confirmed objective response rate of 56% versus 9% in Immunome's ESMO release; and a median time to response of 8.2 months among varegacestat responders.
- Symptom outcomes in RINGSIDE Part B: Immunome reports a worst pain difference of more than 2 points from the first evaluation at week 4. At week 48, least-squares mean changes were -1.50 with varegacestat and +0.59 with placebo on the GODDESS TSS-5 symptom score, and +3.90 and -3.04 on PROMIS Physical Function.
- Treatment duration: median exposure in RINGSIDE Part B was 20.3 months with varegacestat as of October 7, 2025, and median time on treatment in RINGSIDE phase 2 as of April 10, 2024 was 23.1 months in one abstract and 25.4 months in another. Immunome anticipates that patients may receive about 1.5 to 2 years of treatment, pause, and return for treatment.
- Pauses and retreatment: in the NICE appraisal of nirogacestat, clinical experts supported stopping after 2 years if treatment could continue while the tumor was still shrinking or restart if it grew again. The company reported that less than 1% of people in its compassionate use programme continued beyond year 2, and the committee assumed that most patients stop after 2 years. The long-term nirogacestat follow-up publication (Ratan et al. 2025) states that optimal duration and responses after discontinuation are not well defined. The Desmoid Tumor Working Group states that shrinkage can continue after withdrawal, that long-term disease control is achieved in up to 50–70% of patients, and that treatment can be repeated at recurrence.
- Long-term continuous nirogacestat: in long-term follow-up of participants randomly assigned to nirogacestat, the objective response rate was 34.3%, 41.4%, 44.3%, and 45.7% with up to 1, 2, 3, and 4 years of treatment, with no additional progression or death events after year 2. In the French DeNi real-world study, median treatment duration was 16 months, the 1-year PFS rate was 76.2%, and 38 of 49 participants with baseline pain (78%) reported pain improvement.
Treatment goals in guidelines and health technology assessment
Company-stated treatment goals for varegacestat
Expected tumor control with varegacestat in RINGSIDE Part B
| Arm | Progression-free at 1 year | Progression-free at 2 years |
|---|---|---|
| Varegacestat | “94% (95% CI: 85–98%)” | “89% (95% CI: 78–95%)” |
| Placebo | “66% (95% CI: 52–76%)” | “57% (95% CI: 43–69%)” |
Expected symptom relief with varegacestat in RINGSIDE Part B
Treatment duration in RINGSIDE
Treatment duration, pauses, and retreatment with gamma secretase inhibitors
“Optimal duration of treatment and the presence and frequency of additional tumor responses after treatment discontinuation are not well defined. In the setting of limited data, decisions on treatment duration, discontinuation, and rechallenge with nirogacestat are best made in collaboration between patients and their treating clinicians.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term outcomes with continuous gamma secretase inhibitor treatment
“No additional events (progression or death) occurred with additional exposure after year 2” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The ORR was 34.3%, 41.4%, 44.3%, and 45.7% in patients who received nirogacestat for up to 1, 2, 3, and 4 years, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For patients continuing treatment after the first year, the incidence and severity of frequently reported TEAEs decreased through subsequent years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Real-world outcomes with nirogacestat
“The estimated median duration of nirogacestat treatment was 16 months. Partial response and stable disease were observed in 33 (60%) and 17 patients (31%), respectively. The 1-year PFS rate was 76.2%, and 77.0% of patients remained without treatment change at 1 year, including patients with dose reductions. Of the 49 patients with baseline pain, 38 (78%) experienced pain improvement under nirogacestat; 35 (71%) reduced or discontinued analgesics.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Eight out of nine evaluable patients (88%) demonstrated a reduction in tumor volume and improvement in magnetic resonance imaging (MRI) T2-weighted signal intensity. Nine out of 10 patients who presented with pain (90%) reported rapid improvement.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote